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ABSTRACT 
 
 Stroke is the 3
rd
 leading cause of death in the United States.  For this reason, it has 
become our goal to find a drug that is capable of reestablishing intracellular and extracellular Ca
+2
 
flux upon direct binding to the sigma receptor, which can be delivered easily and efficiently. Our 
active research focuses the development of guanidine analogues that can serve as therapeutic 
drugs which target sigma 1 and sigma 2 receptors having a direct effect on Ca
+2 
levels on the cell. 
The use of symmetrical guanidine analogues such as N,N’-di-o-tolyl guanidine (o-DTG) as 
therapeutic drugs for ischemic stroke, is promising due to the fact that neuronal cells can restore 
the proper blood flow and block Ca
+2
 flux into the cell. Our main objective is to be able to develop 
a cost efficient, mild reaction methodology that affords access to guanidine analogues.  The 
synthetic design of the guanidine analogues has been accomplished using copper-catalyzed 
cross-coupling diarylation reaction. This methodology employs a non-expensive guanidine salt 
and substituted aryl iodides along with N,N’-diethylsalicylamides as the key ligand in this strategy. 
Similar methodology was employed for the synthesis of monoarylated amidines employing ligand-
free conditions for the copper-catalyzed cross-coupling reaction. Moreover, efforts to find 
alternative methodologies to access other sigma receptor ligands were accomplished. A new 
method to create N,N’-disubstituted carbamides employed HATU as a peptide coupling agent 
allowing for the formation of carbamides using the inexpensive guanidine nitrate and carboxylic 
acids as starting materials.  
 Studies on the sigma response of the cortical neuron cell were conducted upon 
completion of the analogue design. Moreover, it was discovered that N,N’-di-p-bromophenyl 
guanidine (p-BrDPhG) gave a higher Ca
+2
 inhibition than N,N’-di-o-tolyl guanidine (o-DTG). 
Experimental studies, such as the middle cerebral occlusion were conducted on rats and 
subsequent injections of the p-BrDPhG at 24, 48, and 72 hours’ time marks. When compared to 
o-DTG, it was found that p-BrDPhG is better at reducing the ischemic volume on the brain size. 
1 
 
 
 
 
 
CHAPTER 1 
 
STROKE THERAPEUTICS 
1.1 Introduction 
 
Stroke is the leading cause of disability and the third leading cause of death in the United 
States.  According to American Stroke Association, stroke accounts for more than 150,000 death 
each year, affecting people of all ages, but predominantly those over the age of 55.
1
 Some 
factors associated with stroke are, high blood pressure, high cholesterol levels, obesity, physical 
inactivity, smoking and cardiovascular disease. Due to the increase number of stroke cases, it 
has become imperative to study and develop new therapeutic drugs to minimize neuronal 
damage aid in recovery.  
There are two types of strokes. Ischemic stroke happens when blood clots forms in an 
artery for a short period of time causing dysfunction of brain cells. Hemorrhagic stroke occurs 
when the blood vessel ruptures causing intracranial bleeding occurring at the surface or deep 
within the brain.  
There are two main regions of the brain that are affected upon the occurrence of a stroke. 
The necrotic core which is the region of the brain affected by ischemia subjected to a cascade of 
traumatic effects. The resulting blood flow deficits, leads to low adenosine-5’-triphosphate (ATP), 
reduced energy store levels, ionic disruption, and metabolic failure producing cell death within 
minutes.
1, 2
 The peripheral area called the penumbra, is where collateral blood flow minimizes the 
extent of necrotic cell death. Cells in this area are compromised metabolically, suffering milder 
damage which results in neuronal death as the infarct size expands over a period lasting from 
days to weeks.
3
 Oxygen/glucose deprivation studies in animal models have shown that these 
factors also induced overproduction of lactic acid, leading to an acidic environment in the core 
and the penumbra 5 days post-stroke.
4, 5
  Furthermore, Cytokine cascades involving microglia 
cells also promote and prevent neuronal death after stroke.
6
 Microglial cells under normal 
2 
 
conditions protect the brain by phagocytosing pathogens and promoting tissue restoration.  On 
the other hand, if there is an increase of damage due to stroke, microglia cells become over-
activated promoting expansion of damaged tissue.
7
  
Current emphasis in stroke research has been geared toward finding therapies which 
prevent or minimize expansion of the core size. This can be achieved by restoring the proper 
blood flow, limiting excitoxicity and cytotoxicity, as well as, blocking the influx of Ca
+2
 into the 
cell.
8
 It is also known that neurons can retain enough energy to sustain their resting membrane 
potentials preventing cell disruption and death.
9, 10
 Therapeutic treatments are promising due to 
the fact that neural cells can be repaired after damage has occurred on the penumbra by using 
therapeutic drugs that could target a specific site within the cell. 
 
Continuing research is focused on finding mechanisms and cellular pathways that are 
triggered after a stroke has occurred leading to neuronal death. In vitro studies have shown that 
blocking the N-methyl-D-aspartate (NMDA) receptor prevents neuronal cell death, but clinical 
stroke trials have failed due to the fact that prolonged use of the NMDA antagonists produces cell 
death in mice.
11
 Studies have also shown that the c-Jun-N-terminal kinase (JNK) pathway is 
triggered during neuronal injury. Inhibitors of the JNK have been demonstrated to be 
neuroprotective even when administered more than six hours post-stroke. Unfortunately, when 
given several days later, these inhibitors worsen the stroke injury.
12
  
Tissue Plasminogen Activator (tPA), a Food and Drug Administration (FDA) approved 
blood clot buster, is highly effective if given to the patients three hours after the initial stroke. A 
drawback of this drug is that only 3% of the patients that have suffered a stroke may eligible to 
receive it and it may cause death. If tPa is given after a six hour period it produces adverse 
effects such as hemorrhage and reperfusion.
13-16
 Although tPA prevents an initial expansion of 
the core when blood flow is restored, neuronal death and expansion of the core into the 
penumbra cannot be avoided. Protecting the neurons or diminishing microglia activity is the only 
way to avoid the occurrence of said events. tPA is not considered an ideal stroke medication 
since it is a blood clot buster, and it does not provide any protection to the neurons. The 
3 
 
challenge is finding a therapeutic drug able to provide neuroprotection that can be given to the 
patient with wider therapeutic window and.  
Recently, research performed by Katnik and Cuevas showed that the sigma receptor 
agonist, N,N’-di-o-tolyl guanidine (1) (o-DTG), depresses ischemia-induced calcium elevations by 
70% in response to sodium azide and glucose deprivation in cortical neurons from embryonic rats 
(Figure 1).
17
 By preventing calcium overload, o-DTG protects neurons that are receiving low 
amounts of oxygen due to the low blood flow until oxygen levels stabilize. Ajmo and Pennypacker 
demonstrated that the use of o-DTG administered 24 hours after a permanent embolic Middle 
Cerebral Artery Occlusion (MCAO) in rats reduces the ischemic infarct volume by more than 
80%.
18-20
  In addition, symmetrical guanidines have also been shown to block the sigma receptors 
which regulate Ca
+2 
flux.
21 
 Moreover, Herrera and Cuevas demonstrated that o-DTG inhibited 
acid-induced elevations of Ca
+2
 influx by regulating ASIC-1a channels as well as downstream 
calcium influx pathways.
22
 
 
Figure 1 N,N’-di-o-tolyl Guanidine 
Since there is not an FDA approved drug which provides neuroprotection as a stroke 
treatment, our main goal is to find a therapeutic drug that can provide neuroprotection with high 
affinity and specificity to sigma receptors. DTG analogues are ideal candidates to be evaluated as 
sigma receptor ligands as novel therapeutic drugs for stroke. 
1.2 Sigma Receptors 
Sigma receptors are non-opioid, membrane bound, non-phencyclidine receptors, that 
have been associated with Alzheimer, stroke, cardiovascular diseases, depression, drug abuse, 
and Schizophrenia.
23-26
 These receptors are expressed in the central nervous system and 
peripheral tissues specifically in the liver and pancreas.
27
,
28
 Overexpression of sigma receptors in 
cancer cells suggested its cellular function importance in cancer therapy.
29
 Sigma receptors are 
4 
 
also responsible for the inositol 1,3,5-triphosphate receptor (IP3) modulation at the endoplasmic 
reticulum.
30
 In addition, sigma receptors play a critical role on the signaling cascade for nerve 
growth factor by potentiating neurite sprouting.
31
 Sigma receptors have their own function within 
the cell as neuroregulators and neuroprotectors; this has been demonstrated in both in vivo and 
vitro models.
17, 20, 26
 Moreover, studies have implicated sigma receptors in many physiological 
processes such as learning and memory.
32
  
There are two subtypes of sigma receptors, sigma-1 and sigma-2.
33
 Sigma-1 receptors 
have been cloned,
34
 but the structure of sigma-2 receptors is still unknown. Sigma-1 receptors 
share no similarities to any other mammalian protein, but shares 67% similarity and 30% identity 
with the yeast sterol C8-C7 isomerase (ERG2).
28,34
 The sigma-1 receptor contains 223 amino 
acids, is primarily found in the endoplasmic reticulum and has no structural homology to opioid 
receptors or structural similarity to any neurotransmitter receptors.
23, 28, 34
 Studies performed in 
mammalian cells have shown that inhibiting sigma-1 receptor does not alter cholesterol 
metabolism, but does alter the ability of the cell to bind to benzomorphans, steroids and d 
psychotropic drugs.
35
 Sigma-1 receptors are expressed in cortical neurons and have been shown 
to regulate ion channels that are responsible for neural firing, Ca
+2
 signaling,
19
 K
+
 regulation,
36
 
and neurotransmitter release.
37
  Additionally, the receptor is specifically found in smooth 
endoplasmic reticulum membranes where it forms dimeric complexes with the cytoskeletal 
adaptor protein ankyrin-B, which is involved in cellular function of Ca
2+
 efflux at inositol 1,4,5-
trisphosphate receptors (IP3R) on the endoplasmic reticulum.
38
  
Studies performed by Glennon
39
 and collaborators using highly substituted amines as 
sigma ligands proposed that the sigma-1 receptor contains three hydrophobic binding regions.  
The first region is where the proton donor site is found.  The primary hydrophobic site is farther 
away from the proton donor site and accommodates aromatic moieties. In addition, this study 
reports the existence of a secondary binding site capable of binding bulkier groups.
39, 40
 
Part of the ability of sigma receptor ligands to provide neuro-protection during a stroke is 
due to their regulation of intracellular calcium and their association with glutamate receptor 
neurotransmitter release.
41
 Zhang and Cuevas showed that sigma-1 receptors directly couple to 
5 
 
inotropic glutamate receptors, and modulate voltage-gated calcium channels by altering the 
channels biophysical properties.
19
  Selective inhibition of these channels during ischemia 
accompanied by some degree of neuroprotection has been previously studied.
42
  
Acid Sensing Ion Channels (ASIC), which are regulated by sigma receptors, have also 
been associated with neuronal injury following ischemic stroke.
22, 43
ASIC are activated by 
extracellular protons and are highly permeable to Na
+
 ions. It was found that ASIC1-a, an ASIC 
subunit isoform, forms homomeric channels which are also Ca
+2
 permeable.
44
 Acidosis caused by 
accumulation of lactic acid during ischemia is directly related with the activation of ASIC1-a.
45
 
ASIC1-a triggers NMDA, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid (AMPA), as 
well as, voltage-gated Ca
+2
 channels which are responsible for the intracellular Ca
+2
 elevation 
during acidosis.
22
 Herrera and coworkers showed that inhibition of ASIC1-a by activation of 
sigma-1 prevents the  accumulation of intracellular Ca
+2
 and neuronal death associated with 
ischemic stroke.
22
 Due to the fact that sigma receptors regulate multiple cellular functions, it is a 
potential target for stroke therapeutics in delay time points.  
Sigma receptors are known to bind a variety of pharmacological agents. Some examples 
are showed in Figure 2 including the sigma-1 selective antagonist haroperidol (2),
46
 Sigma-1 and 
2 agonist opipranol (3),
46
 sigma agonists (+)-pentazocine (4),
47
 and dextromethorphan (5).
48
  
 
Figure 2 Examples of Sigma Receptor Ligands 
Glennon’s structure/affinity studies of compounds containing amines have found that 
extension of the aliphatic chain between the amine and the phenyl ring by 4 or 5 carbons 
increases the binding affinity of the compound to the sigma-1 receptor (Figure 3). Compounds 
containing more than one amine moiety exhibited high binding affinity to sigma-1 receptor (Ki=1.4 
6 
 
nM), such as, BD-1047(6), a sigma-1 receptor antagonist having a phenyl ring with halogen 
substitutents (Ki=0.16 nM) (7).
39
 
 
Figure 3 Examples of SAR Compounds for Sigma Receptor 
Vilner’s
49
 studies showed that sigma-2 receptors are involved in Ca
+2
 release from the 
endoplasmic reticulum and the mitochondria. It is also suggested that sigma-2 receptors are 
formed by histones or could also bind histone proteins.
50
 Sigma-2 receptors are overexpressed in 
tumor tissues, and its ligands could be used as in diagnostic imaging.
50, 51
 On the other hand, the 
sigma ligand PB-28 (8) induces cytotoxicity in rat glioma, breast cancer adenocarcinoma and 
neuroblastoma cells.
52, 53
 Berardi and coworkers in 2006 demonstrated that PB-28 is a potent 
sigma-2 receptor agonist (Figure 4).
54
 It was observed that PB-28 inhibited the Ca
+2
 release 
through the IP3 receptors in SK-N-SH neuroblastoma cells. Incubation of PB-28 inhibited the 
increase of cytosolic Ca
+2
 evoked by caffeine, carbachol or histamine.  
 
Figure 4 PB-28 Sigma-2 Receptor Agonist 
There are many drugs that act as sigma receptor ligands. Our main interest is the use of 
guanidines as possible pharmacological stroke therapies.  Guanidines have been previously used 
as sigma receptor ligands; however it is thought that alterations of their structures will create 
compounds which are much more effective as neuroprotectors for use in pharmacological stroke 
therapies.  
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1.3 Guanidines’s Role as Sigma Receptor Ligands 
In 1988, Kavanaugh and Keana developed a selective ligand for sigma receptors. Assays 
in guinea pigs brains showed that [
3
H]N3DTG bound reversibly and selectively to sigma receptors. 
The reversibility of the radiolabeled [
3
H]N3DTG compared to [
3
H]DTG were identical. These 
finding suggested that this ligand could be used as a detect ion tool for the characterization of 
sigma receptors.
55
 In the 1990’s, in vitro binding studies were performed using guinea pig brain 
membrane suspensions to demonstrate the affinity of symmetrical and unsymmetrical guanidines 
to sigma and PCP receptors. It was found that symmetrical guanidines with more hydrophilic and 
bulkier substituents on the same position of the phenyl ring had lower affinities for sigma 
receptors.
56
 
Moreover, Gee and collaborators studied the ability of guanidines to bind selectively to 
sigma receptors, finding that unsymmetrical guanidines containing N-naphthyl and N’-methyl-N’-
phenyl groups (9) showed higher selectivity (IC50 = 100 nM) to the phencyclidine (PCP) site of the 
NMDA receptor than to the sigma receptors (Figure 5).
57
 
 
Figure 5 N-(3-azidophenyl)-N-methyl-N'-(1-naphthyl) guanidine 
Intensive structural-activity studies were performed on N,N’-diaryl guanidines and their 
ability to selectively bind to NMDA receptors as antagonists. Symmetrical and unsymmetric al 
guanidine compounds were synthesized and evaluated in vitro radioligand displacement assays 
with rat and guinea pig brain membrane homogenates.
58
 The selectivity studies on unsymmetrical 
guanidines showed that the affinity of the guanidines to NMDA and sigma receptors is dependent 
on the additional substituents on the N-bearing aryl groups. The studies showed that disubstituted 
guanidines have higher affinities to sigma receptors (Figure 6). 
58
 
8 
 
 
Figure 6 Unsymmetrical Di-substituted Guanidine versus Tri-substituted Guanidines 
Electron donating groups such as methyl and ethyl produced tri and tetra-substituted 
guanidines which had the highest affinities for NMDA receptors.
58
 It was also suggested that the 
substitutions on the N-bearing the aryl groups decrease the degrees of conformational flexibility 
compared to the disubstituted guanidines, which lead to a preferred conformation that might 
influence the affinity to sigma receptors.   
The success of the pan-selective sigma agonist o-DTG as a therapeutic agent for the 
treatment of stroke has prompted attempts to improve the efficacy and/or potency  of this 
compound. It was believed that the high selectivity of o-DTG to the sigma-1 and sigma-2 
receptors makes this compound a potent candidate for stroke therapeutics compared to other 
sigma receptors ligands.
59, 60
 Analogues of the parent compound (o-DTG) are thought to increase 
the membrane permeability, receptor binding affinity and specificity of the agonist. Synthesis of 
guanidines with aryl substitutions can represent a technical challenge in many instances. This led 
to the thought that a new methodology for the formation of N,N’-disubstituted guanidines was 
necessary.  
The goal is to generate a wider library of compounds using new methodologies to create 
substrates for sigma receptors which mediate cellular responses in vitro and in vivo with greater 
efficiency than DTG and to determine structural/affinity relationships for these compounds. To be 
able to accomplish our goal, it is important to demonstrate the classical ways to form guanidines, 
as well as show the advantages and disadvantages of these methodologies.   
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CHAPTER 2 
 
EXHISTING METHODS FOR ARYL  
GUANIDINE, AMIDINES AND CARBAMIDES SYNTHESIS 
2.1 Guanidine Methodologies 
Guanidines are considered by many scientists to be rare compounds . Due to the high 
polarity and basicity of guanidines, their synthesis represents a difficult challenge for chemists. 
These compounds are used as intermediates for important medicinal applications and catalytic 
processes.
57, 61-65
  The existing methodology available to make guanidine based structures is 
limited due the required use of expensive and toxic starting materials or high temperatures 
necessary to produce them.
66
  
There are two basic methods to make guanidines: guanylation and guanidinylation.
67
 
Batey defines guanylation as incorporation of an amine to form a guanidine.
68
 In many cases 
there is concerted addition followed by an elimination of a good leaving group.
69-72
 Common 
reagents are employed for the guanylation reactions.
73-77
  Some of these guanylating reagents 
are showed in Figure 7. 
 
Figure 7 Guanylating Agents 
Guanidinylation, on the other hand, is when an electrophile reacts with a nucleophilic 
guanidine to produce highly substituted guanidines. The NH2 of the guanidine is introduced by an 
aryl, alkyl halide or alcohol. Some protections of guanidines are considered guanidinylations.  
Traditional guanylation methods have included the addition of cyanogen bromide to 
aniline,
78
 or the addition of amines to functionalized thioureas.
61
 A classical guanylation method 
involves a cyanogen bromide addition to amines to make symmetrical and unsymmetrical 
guanidines; this methodology was fully explored in the early 1990’s.
58, 78, 79
 It was clearly 
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demonstrated that di-, tri- and tetra-substituted guanidines could be made by this methodology in 
one or two steps as shown in Figure 8.  
 
Figure 8 Cyanogen Bromide Addition to Amines to form Symmetrical Guanidines 
A direct method to make symmetrical N’N’-disubstituted guanidine is performed by 
cyanogen addition to amines using ethanol as solvent (Figure 8). The second method employs 
ether as solvent to form a cyanamide followed by addition of an amine salt to form symmetrical 
and unsymmetrical disubstituted guanidines.  Substituted anilines in the ortho, meta and para 
position were employed. Harsh starting materials and high temperatures are necessary to be able 
to achieve the final product. 
It was also shown that this same methodology could be applied for the formation of 
unsymmetrical tri and tetra-substituted guanidines.  For these methodologies, two different routes 
were taken (Figure 9). In the first reaction, a secondary amine is used as starting material and 
reacts with cyanogen bromide to form the cyanamide (25) followed by an amine addition to form 
tri-substituted guanidines (26). The second one uses an unsubstituted cyanamide which is 
alkylated using NaH in THF to form a secondary cyanamide followed the addition of the 
secondary amine salt to form tetra-substituted guanidines (27). 
11 
 
 
Figure 9 Formation of Unsymmetrical Guanidines 
Methods utilizing substituted thioureas are not direct, requiring the separate preparation 
of each precursor. A recent direct guanylation of thioureas employed bismuth iodide or bismuth 
nitrate as catalysts. Five examples of reaction parameters are presented in table 1.  
Table 1 Guanylation of Thioureas 
 
Previous studies showed that this reaction needed stoichiometric amounts of the bismuth 
compounds.
80
 Reaction conditions featured shorter reaction times with higher reactivity. The 
proposed mechanism for these reactions is showed in Figure 10. The authors suggested that 
Bi(III) behaves as a soft Lewis acid coordinating to the thiourea. The thiourea reacts with Et 3N 
forming a carbodiimide by thiourea desulfurization and is trapped on the amine to form the highly 
substituted guanidine. 
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Figure 10 Proposed Mechanism for the Bi(III) Catalyzed Guanylation 
One of the first guanidinylation methodologies developed was the conversion of primary 
and secondary alcohols to guanidines under Mitsunobu conditions.
81
 Other methodologies 
involved the protection of guanidines using BOC to produce bis -BOC-protected terminal 
guandines.
63, 82, 83
  
In 2003, Powell and Batey demonstrated that a guanylation reaction followed by a 
guanidinylation reaction was possible by direct addit ion of vinyl bromide to form highly substituted 
guanidines.
68
 For this type of reaction a two-step process is required. The first reaction where a 
guanylation is required allowed the formation of the protected guanidine from 78 to 96% yields 
(Table 2). Boc protected starting material provided higher reactivity compared to the Cbz 
protected (entry 1-2). This reaction was followed by a guanidinylation reaction for the formation of 
highly substituted guanidine in high yields  
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Table 2 Batey's Guanidinylation 
 
With the development of guanidines as sigma receptor ligands, it was thought that other 
types of moieties could be used as possible guanidine analogues to produce additional sigma 
receptor agonists.  Amidine is one such moiety, which has the added benefit of being an anti -
inflammatory agent. Such compounds could also be useful as potential anti-stroke agents. 
2.2 Amidine Methodologies  
Amidine containing compounds have showed antiviral and anti-inflammatory activity due 
to their unique structural properties.
84-86
 Amidines are also important precursors used in the 
formation of quinazolinones
87
 and benzimidazoles
88
 which are used in the treatment of obesity.
89
 
Recently, Ilas 
90
 and Kikelj showed that 3,4-dihidro-1,4-benzoxazine derivatives (38)  containing a 
amidine moiety have similar anti-aggregatory properties as arginine, which is an essential 
component for most anti-thrombotic therapeutic drugs (Figure 11).  
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Figure 11 3,4-dihydro-2H,1,4-benzoxazine derivatives 
The final modification of the benzamidine moiety and the central 1,4-benzoxazine leads 
to a antithrombotic agent with an IC50 of 0.73 μM. Pinner reaction conditions only allowed 
accessing the amidine moiety in low yields. 
Standard methodologies for substituted amidines often utilize Pinner reaction protocols.
91, 
92
 Recent studies performed by Caron
93
 and coworkers showed a two-step reaction for the 
formation of amidine salts using nitriles and amines as starting materials (Figure 12). These 
reaction conditions produced substituted amidines with overall yields of up to 74% 
 
Figure 12 Preparation of Substituted Amidine Salts 
Common amidine methodologies generally employ the addition of amines to nitriles 
substituted with electron-withdrawing groups.
94, 95
  The nitrile activation is usually promoted 
through the use of relatively costly catalysts such as La,
96, 97
 Yb,
98
 FeCl3,
99
 AlCl3,
100
 use of high 
temperatures
86
 or stoichiometric amounts of CuCl.
101
 As an example, Garigipatti employed 
alkylchloroaluminun amides, which are generated from trimethyl aluminum and amine 
hydrochloride, or ammonium chloride for the formation of amidines.
102
 Figure 13 illustrates this 
methodology, which produces easy access to unsubstituted amidines with yields up to 96%.  
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Figure 13 Amidine Formation from Nitriles 
Bae
103
 and Chang developed a multicomponent reaction involving copper-catalyzed 
coupling using sulfonyl azides and a wide variety of alkynes and amines as starting materials 
(Table 3).  
Table 3 Copper-Catalyzed Multicomponent Reaction (MCR) 
 
This efficient reaction was carried out using catalytic amounts of copper in presence of 
THF which resulted in 23 examples with yields up to 99%.  The reaction conditions tolerated a 
wide variety of electron-donating and electron-withdrawing, as well as, hetero-alkyne substrates.  
A pathway was proposed that first involves formation of the copper-acetylide.  The 
ketenimine intermediate would then form by the nucleophilic attack of the Copper-acetylide to 
azide nitrogen followed by rearrangement. At the same time, a molecule of N2 will be a released. 
As a final step, amination across the C=N bond of the ketenimine followed by tautomerization 
would lead to the product as showed in Figure 14.  In 2008, Bae and Chang postulated that this 
three component reaction could be carried out in one step employing catalytic amounts of copper 
16 
 
followed by copper-intramolecular N-arylation for the formation of 2-H-1,2,4-benzothiadiazine 1,1-
dioxide in moderate yields.  
 
Figure 14 Copper-Catalyzed Three-Component Reaction Pathway 
Xu
104
 and Li showed that substituted amidines could be made by employing diethyl 
azodicarboxylate for the formation of an enamine by activating the α and β-hydrogens of a tertiary 
amine followed the by the addition of sulfonyl azide. Table 4 shows that these reaction conditions 
afforded 24 different sulfonyl amidines with 15 to 91% yields.  The formation of highly toxic side 
products in this reaction required cautious handling of the reaction.  
Table 4 Sulfonyl Amidine Synthesis promoted by DEAD 
 
In 2010, additional studies performed by Xu
105
 and collaborators demonstrated that highly 
substituted amidines could be formed by employing CuCl as a catalyst.  It was demonstrated that 
CuCl could catalyze the reaction to make sulfonyl amidines with similar results as Weng’s work  
had shown previously. Expansion on these results focused again on using CuCl as a catalyst for 
the formation 5 and 6 member cyclic amidines, which were produced with moderate yields, as 
shown in Table 5. 
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Table 5 Copper Cholride Catalyzed Synthesis of Cyclic Sulfonyl Amidines 
 
Anbazhagan
106
 demonstrated that palladium-catalyzed cross-coupling allowed the 
formation of monoarylated amidoximes with low to moderate yields (Figure 15). Twelve examples 
demonstrated that the reaction conditions tolerated electron-withdrawing as well as electron-
donating substituted aryl bromides with yields up to 87% yields . 
 
Figure 15 Palladium-Catalyzed Cross-Coupling of o-methylamidoxime 
  The synthesis of monoarylated amidines hasn’t been fully developed; we envisioned to 
find a general and useful methodology that could access a wide variety of amidine moieties. The 
goal was to employ mild conditions and inexpensive reagents for the formation of monoarylated 
amidines with the end result being their effectiveness, compared to o-DTG, as post-ischemic 
stroke therapeutics.  As methodology for the formation of amidines has been explored, it was also 
important to expand our knowledge on alternative structures that can be also be used as possible 
sigma receptor ligands. We also wanted to investigate the methodologies available for the 
formation of carbamides.  The goal was to develop as many possible structures that were similar 
18 
 
to o-DTG; by employing inexpensive starting materials, avoiding harsh or toxic reaction conditions 
and producing high yields.  
2.3 Carbamidine Methodologies 
Synthesis of carbamides employing amidines and guanidines as coupling agents has 
been widely used  for the formation of medicinal compounds such as N,N’-carbonyldiimidazole,
107
  
3-substituted-4(3H)-quinazolinones,
108
 Microcin B17
109
 and cyclic ureas.
110
 There are two 
important studies that demonstrated the development of the C-N bonds employing amidines and 
guanidines and guanidine salts for the formation carbamides. In 1976, Stolyarchuck and 
collaborators synthesized carbamides employing guanidines and 5’-substituted furoyl chlorides 
for the formation of mono and disubstituted furoyl guanidines.  
 
Figure 16 Formation of N,N’-disubustituted Carbamides 
These products were pharmacologically tested as ligands for the cholinergic nicotinic 
receptor, and found to act as central nervous system stimulants. The best results, in terms of 
reduced toxicity, were found when halides such as bromo or chloro were introduced in the 5’ 
position of the furoyl chloride (Figure 16). The reaction conditions allowed for the formation of the 
disubstituted products with yields as high as 25 %. 
Recent studies by Castanedo
111
 and coworkers showed that it was possible to form 
amides by employing amidines and benzoic acid as starting materials and using 2-(1H-7-
Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uranium hexafluorophosphate methanaminium 
(HATU),
112, 113
 as a coupling agent (Figure 17).  
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Figure 17 Coupling Agent 
The amide formation was used as the intermediate of the reaction to form 1,3,5-
trisubstituted 1,2,4-triazoles as the final product. The results showed that with this methodology, 
22 different substituted triazoles could be produced, the reactivity being dependent on the first 
reaction which involved the formation of the amide by C-N coupling. Various bases were 
employed, with N,N’-diisopropylethylamine (DIPEA) achieving the highest reactivity with yields up 
to 99% and reactions time up to 18 hours (Figure 18). 
 
Figure 18 Formation of Acylamidine 
This lead to the thought that N,N’-disubstituted guanidines could be used for the 
formation of symmetrical N,N’-disubstituted carbamides, employing similar methodologies. Our 
main goal is find a novel methodology that provides easy access to the desired products in a one-
step synthetic pathway avoiding the use of harsh and expensive starting materials. Copper-
catalyzed reactions were used as an excellent alternative for the development methodologies of 
guanidines and amidines.  
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CHAPTER 3 
 
COPPER-CATALYZED CROSS-COUPLING METHODOLOGIES 
3.1 Introduction 
Previous research has demonstrated that symmetrical N,N’-di-substituted guanidines, 
such as o-DTG (1), show high affinity to sigma receptors.
17
  Moreover, researchers have showed 
that these types of moieties have the capability to provide neuroprotection by decreasing the 
infarct volume in rats.
20
 Our main goal is to apply copper-catalyzed cross-coupling as a new way 
to access guanidine analogues. Representative examples of copper-catalyzed cross-coupling 
reactions are presented explore the possibilities of applying this reaction to our substrates. 
Copper-catalyzed cross-coupling methodologies have become an important key step for 
industrial and pharmaceutical applications.
114
 Many research groups try to find better reaction 
conditions for the copper-catalyzed cross-coupling conditions for the C-N,
115
 C-O,
116, 117
 and C-
S
118
 bond formations, to achieve higher reactivity and a wider substrate scopes.  In many cases, 
copper-catalyzed cross-coupling reactions are used as an inexpensive alternatives to Ullmann,
119
 
Goldberg,
120
 and palladium
121-123
 coupling methodologies. The break though in copper catalysis 
was the use of ligands such as: 1,10-phenanthrolines (67),
124
 cyclic diketones (68),
125
 
salicylamides (69),
126
 phosphines (70),
127
 diols (71),
128
 amino acids (72),
129, 130
 and diamines 
(73).
115,131
 These allowed for further improvement of the reaction’s efficacy (Figure 19). 
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Figure 19 Ligands used in Copper-Catalyzed Reactions 
Major improvements of these copper-catalyzed cross-couplings have made a great 
impact in the development of wide variety of novel medicinal compounds. Several recent 
applications of copper-catalyzed reactions involving amidine and guanidine moieties as 
intermediates have been published. Specifically, they have been exploited for the formation of 
benzimidazoles (74),
62
 quinazolinones (75)
132
 and disubstituted imidazolones (76)
133
 which can 
be used as important antibacterial, anti-inflammatory and of alkaloids intermediates (Figure 20). 
 
Figure 20 Benzimidazoles, Quinazolines and Di-substituted Imidazolone 
 
Fritz Ullmann
119
 and Irma Goldberg,
134
 in the 1900’s, reported the first copper mediated 
aromatic nucleophilic substitution reactions. Ullmann condensation reaction can be performed by 
a copper-mediated reaction in stoichiometric or catalytic amounts. The initial Ullman reaction 
conditions allowed for the formation of diaryls from aryl halides (Figure 21). In 1903,
135
 the 
Ullmann Condensation reaction showed that it was possible create C-N,
115
 C-O
116, 117
 and C-S
118
 
bonds by utilizing aryl halides as starting materials with anilines, phenols or thiophenol. Goldberg 
22 
 
condensation reactions involved the C-N bond formation between aryl halides and amides (Figure 
21). Theses methodologies required harsh reaction conditions such as high temperature, strong 
base or the use of stoichiometric amounts of copper. Usually theses methodologies can be 
achieved in moderate yields, and generally suffered low reactivity with low yields when performed 
in larger scale. 
 
Figure 21 Ullmann and Goldberg Reactions 
Continuous efforts have been made to find ways to improve Ullmann amination and 
Goldberg amidation methodologies. Recently, Major advances were achieved in the Modified 
Ullmann condensation reactions, as well as, copper-catalyzed cross-coupling aminations with the 
help of ligands. Extensive reviews of C-N,
136
 C-O,
116, 117
 and C-S
118
 bond formations demonstrate 
the advantages and drawbacks of these reactions. 
3.2 Copper-Catalyzed Cross-Couplings  
3.2.1 Amides 
 Major breakthrough in 2001 on copper-catalysis was made by Klapars,
131
 and Buchwald 
using catalytic amounts of copper salts with the aid of 1,2-diamine ligands (Table 6). This 
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methodology was able to demonstrate that copper can catalyze a wide variety of amides and N-
heterocyclic compounds. 
Table 6 Copper-Catalyzed Amidination  
 
Importantly, copper iodide was used in amounts as low as 1 mol%. This work set the 
bases for the future copper-catalyzed cross-coupling reaction developments in catalytic amounts 
with milder conditions. The reaction conditions allow for the formation of the product with a wide 
substrate scope and displaying yields up to 99%.  
Moreover, mechanistic studies were performed by Strieter
137
 and Buchwald to explain the 
copper catalytic cycle involving 1,2-diamine ligands. At this time, different copper sources with 
three different oxidation states: Cu(0), Cu(I) and Cu(II) had been used with great success. The 
initial hypothesis suggested that the active oxidation state is Cu(I).
138
 Other studies showed that 
Cu(II) species decay to Cu(I) in presence of an amine.
139
  Strieter
140
 and Hartwig’s
141
  previous 
studies showed that Cu(I) amidates can serve as intermediates during the N-arylation process.  
The amount 1,2-diamine controls the coordination environment around the copper. Strieter 
demonstrated that a 1,2-diamine ligated Cu(I)-amidate can serve as the reactive species that 
activates the aryl halide. With the results from the kinetic studies Strieter showed there could be 
two possible mechanisms of activation. The first route suggested by Guo
142
 involves the 
formation of η
2
 complex between the Cu(I)-amidate and the aryl iodide during the rate limiting 
step (Figure 22). On the second possible route the aryl iodide coordinates with the Cu(I)-amidate, 
facilitated by para electron-donating groups of the aryl iodide. 
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Figure 22 Cu(I) Amidate Promoted Aryl Iodide Activation 
This is followed by an inner-sphere single electron transfer from the Cu(I) species to the 
aryl iodide. Cu(II) is generated by addition to a radical ion with no charges in bonding; electron-
deficient para-substituted aryl iodides will help in the latter process. Strieter and Guo’s 
mechanistic studies provided important information about the ligand’s role in the copper- 
catalyzed amidation reactions. 
Recently, Xu
9
 and Wolf explored the development of highly substituted amides by the use 
of ligand-free copper-catalyzed cross-coupling of aryl bromides and aryl iodides with primary 
amides (Figure 23). Only 8 examples for the substrate scope were presented in moderate to high 
yields. 
 
Figure 23 Ligand-Free Copper Catalyzed Amidation 
Aryl iodides exhibit higher reactivity than the aryl bromides. Copper(II) oxide in 5 mol% 
was used as catalyst and NMP as solvent at 80 °C to 110 °C. In addition, the use of 4 equivalents 
of bases such as Cs2CO3 or NaOtBu was necessary for the reaction to proceed. The reaction 
times varied from 18 to 48 hours depending on the substrate used.  
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3.2.2 N-Heterocycles 
In 2002, Klapars
143
 and Buchwald showed an extensive investigation on structure-activity 
relationship of diamine ligands for the catalytic copper-catalyzed cross-coupling reaction between 
aryl halides and amides. N,N’-dimethyl diamines (73a) showed higher reactivity and yields than 
those that were highly substituted or contained bulkier groups (Table 7).  
Table 7 Copper-Catalyzed N-Arylation of Nitrogen Heterocycles 
 
The reaction conditions allowed for the formation of the products in excellent yields. In 
2004, Antilla
144
 performed an extensive review showing that pyrazoles, pyrroles, indazoles, 
triazoles, could be catalyzed by copper cross-coupling reaction using diamines as ligands as well. 
This methodology allowed the formation of N-Heterocycles with excellent yields.  
3.2.3 Amines 
With the new development in the catalytic Goldberg reactions, it was also necessary to 
find better conditions for the Ullmann aminations.  In 2002, Kwong
128
 and Buchwald reported a 
mild and efficient copper-catalyzed cross-coupling reaction to introduce C-N bond using amines 
and aryl halides as starting materials (Table 8). Ethylene glycol (71) was used as ligand and 2-
propanol was used as solvent in air atmosphere. This reaction covered a wide substrate scope 
employing 5 mol% of copper iodide. Extension of the substrate scope showed that aryl bromides 
could be used for the amination reaction with moderate to high yields .  
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Table 8 Kwong’s Copper-Catalyzed Amination using Ethylene Glycol    
 
Later on, Kwong
126
 and Buchwald found that the copper-catalyzed cross-coupling of aryl 
bromides with primary amines could be accomplished employing salicylamides as major anionic 
O-donor ligand, even in solvent free conditions (Table 9). Substrate scope included ortho, meta 
and para-substituted aryl bromides, as well as, a wide variety of primary aliphatic amines. The 
reaction conditions allowed the use of lower amounts of primary amine substrates; N,N’-
diethylsalicylamide (69) provided with the highest reactivity, and the copper:ligand ratios were as 
low as 1:1.  The reaction conditions allowed for moderate yield in solvent free conditions.  Other 
studies were also explored for intramolecular copper-catalyzed amination, showed that copper 
reactions can be carried out under mild conditions with similar reactivity.   
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Table 9 Solvent-Free Copper-Catalyzed Cross-Coupling of Aryl Halides 
 
Ma
129
 and Cai showed that copper catalyzed amination reactions were carried out by 
employing L-proline (72) or N-methylglycine as ligands. The copper catalyzed reaction called for 
mild conditions allowing the formation of aliphatic amines, cyclic amines and anilines (Figure 24).   
 
Figure 24  Copper-Catalyzed Arylation using Amino Acids as Ligands 
The arylation process employing electron-withdrawing and electron-donating aryl iodides 
allowed for the formation of substituted amines with yields up to 91%. Moreover, in 2006, 
Shafir
125
 and Buchwald found that cyclic β-diketones (68) could undergo copper-catalyzed 
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amination with high selectivity at room temperature. A wide variety of commercially cyclic β-
diketones were tested (Table 10).   
Table 10 Copper-Catalyzed Aminations with Cyclic β-diketones 
 
The cyclic β-diketones showed faster conversion times compared to those of N,N’-
diethylsalicylamides (69) which had been previously reported. A series of para-substituted 
iodobenzenes ranging from electron-donating to electron-withdrawing groups were employed. 
Interestingly, the double arylation of a 1,4-diiodobenzene was achieved with high yields. These 
types of coupling reactions normally allow for the formation of C-N and C-O as well. In this case, 
substrates containing OH were not affected by showing C-O bond side products. Furthermore, 
when more complex substrates were used the amination always occurred on the aliphatic amine.  
In 1998, Ma
145
 and coworkers showed that optically pure α-amino acids could be 
arylated, retaining its configuration, and employing ligand-free conditions (Table 11). The 
products formed by the copper-catalyzed cross-coupling reaction are versatile intermediates for 
the synthesis of indolactam-V,
146
 and benzolactam-V8, which are protein kinase C activator. The 
reaction conditions allow for lower temperatures, but longer reaction times were needed to 
achieve greater product formation. 
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Table 11 Ma's Copper-Catalyzed Cross-Coupling of Aryl Halides with α-Amino Acids 
 
It was found that for bulkier α-amino acids the reactivity was higher, and no racemization 
was noticed in most cases. Some examples were presented of α-amino acid scope with yields up 
to 92%. 
Later on, in 2009, Xu
9
 and Wolf used Cu2O in catalytic amounts in presence of water and 
N-methyl-2-pyrrolidone (NMP) in 1:1 ratio for the arylation of ammonia (119).   
Table 12 Formations of Anilines by Ullmann Reaction 
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This reaction conditions allowed for the formation of substituted anilines in high yields 
when employing aryl bromides and aryl iodides at 80 °C (Table 12). The great advantage of this 
reaction was that it allows for easy handling of aqueous ammonia with no loss of reactivity.  The 
main disadvantage of this reaction was that microwave irradiation at 150W and higher 
temperatures were necessary to allow high conversion to the desired aniline products. Table 12 
shows some of the examples of substrate scope most of them with excellent results.   
3.2.4 Aminoalcohols 
 Furthermore, advances in the copper-catalyzed cross-coupling reactions lead to the 
investigation of N-versus O-Arylation of aminoalcohols (Table 13).
124
  The results showed that to 
achieve N-arylation over O-arylation was achieved by employing tetramethylphenanthroline (67) 
as a ligand.  
Table 13 N-Arylation versus O-Arylation of Amino Alcohols 
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In addition, a four carbon chain or more is needed between the NH2 and the OH. 
Electron-donating and electron withdrawing substituted aryl iodides were used. It was also shown 
that the amination process tolerated a variety of aryl iodides as well as heterocyclic compounds 
achieving high yields. Primary amines containing four carbon chain with complex structures 
containing OH were also tolerated showing yields up to 93% with a N:O selectivity of 50:1.   
In 2002, Job
147
 and coworkers showed that amino alcohols (124) could be arylated by 
ligand-free copper-catalyzed reaction conditions (Table 17). Employing DMSO and H2O as co-
solvents allowed for the arylation of amino alcohols at 90 °C. High selectivity to the NH was 
noticed over the OH.  
Table 14 Copper-Catalyzed Arylation of β-Amino Alcohols 
  
Some examples of N-arylation showed that copper could be used in catalytic amounts as 
low as 2.5 mol%, while allowing the product formation in moderate to high yields.   
3.2.5 Guanidines 
In 2003, Batey
62
 and collaborators showed that copper catalyzed reactions can be used 
for the formation of important medicinal compounds.
148
 A copper-catalyzed intramolecular aryl 
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guanidinylation for the formation of 2-aminobenzimidazoles was under studied (Table 15). For 
this investigation tri and tetra substituted guanidines containing o-bromosubstituted aryl group in 
the imine portion of the guanidine were employed. Several copper catalyst were used finding that 
5 mol% of CuI and 10 mol% of 1,10-phenanthroline (67) proved optimal for the cyclization 
reaction to proceed. In addition, a palladium catalysts were tested finding that 10 mol % of 
Pd(PPh3)4 was the most suitable catalyst. 
Table 15 Intramolecular Aryl Guanidinylation of Aryl Bromides 
 
Both reaction conditions allow the formation of 2-aminobenzimidazoles with yields up to 
98%. Electron-donating and electron-withdrawing groups on the phenyl ring were tested. In most 
cases copper was more powerful for the cyclization of the guanidines than palladium was. 
In 2009, Deng
149
 showed formation of benzimidazoles using guanidines (130) and 
amidines as stating materials for the copper catalyzed amination process . Deng’s goal was to 
33 
 
achieve a double amination of the guanidines or amidines for the formation of the benzimidazoles 
(Table 16). To be able to achieve the double addition, di-substituted and tri-substituted aryl 
halides were employed, and N,N’-dimethylethylenediamine (73) was used as ligand.   
Table 16 Copper-Catalyzed Guanidine Cyclization 
 
The double amination was possible by using 4 equivalents of Cs2CO3 and increasing the 
temperatures as high as 165 °C. The reaction conditions allow for the formation of the 
benzimidazoles in low to moderate yields.  
 Furthermore, Deng
149
 showed that guanidines salts could be monoarylated using milder 
conditions. The copper catalyzed arylation of guanidines conditions using 10 mol% CuI and 20 
mol% of N,N’-dimethylethylenediamine (73) were required to achieve high reactivity.  For this 
study, only one guanidine salt was tested for the monoarylation process, and all the aryl iodides 
employed were para substituted. Seven examples in where included electron-donating groups, 
demonstrating, electron-withdrawing substituted aryl iodides, achieving yields from 35% to 93% 
(Table 17). 
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Table 17 Monoarylation of Guanidine Salt 
 
 With these breakthroughs in guanidinylation processes, a door was opened for the 
possibility of finding new methodology that will be able to provide easy access N,N’-disubstituted 
guanidines.  
3.2.6 Amidines 
Deng
149
 observed that it was possible to cyclize amidines by using 1,2-diiodobenze for 
the formation of benzimidazoles, but uncyclized monoarylated amidine was present in the 
reaction as a side product. Harsh conditions such as: high concentration of the diamine ligand 
and temperature as high as 170 °C were required for the cyclization to go forward. Some of the 
examples of products with yield up to 66% of the cyclized product and as high as 35% of the 
monoarylated amidine are presented in table 18. These results provided vital information that 
allowed for further exploration of copper-catalyzed cross-coupling reaction for the formation of 
monoarylated amidines as main product. New methodologies to control the formation of the 
monoarylated product will be necessary to access new analogues as potential post-stroke 
therapeutics. 
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Table 18 Benzimidazoles Formation 
 
In 2008, Brasche
88
 and Buchwald presented a new synthesis of benzimidazoles 
employing monoarylated benzamidines as starting material and Cu(OAc)2 as catalyst under 
ligand-free reaction conditions (Table 19). Oxygen was used as an oxidant to generate water as 
side product. A wide variety of monoarylated amidines (139) were synthesized by known 
procedure of aniline addition to carbonitriles.
150
 
Table 19 Benzimidazoles Formation from Monoarylated Benzamidines 
 
The substrate scope showed that Me, CF3, OMe, Cl, or TBS ortho-substituted 
benzamidines tolerated the reaction conditions. The o-methyl substituted benzamidines cross-
36 
 
coupling reaction allowed for the formation of the cyclized product from moderate to high 
reactivity.  
In 2008, Yang
87, 151
 and Zhao showed that amidine could be cyclized for the formation of 
benzimidazoles. For this ligand-free copper-catalyzed reaction o-haloacetoanilides and amidine 
salts were used.  It was also shown in the optimization reaction the cyclization can be carried out 
by employing N,N-dimethylethylenediamine as ligand and DMF as solvent obtaining similar 
results. It was found that uncyclized monoarylated product can be formed, but they thought that 
these substrates had poor medicinal value. Thirteen examples of 2-substituted Benzimidazoles 
showed yields up to 89% when using DMSO as solvent (Figure 25).  
 
Figure 25 Copper Catalyzed Cyclization of Amidines to Form Benzimidazoles 
Yang also proposed that in the copper catalyzed cascade reaction Cs2CO3 was needed 
to free the amidine while copper bromide will coordinate to the o-haloacetoanilide (Figure 26). 
The reaction mechanism was followed by an oxidative addition (146) and displacement of Bromo. 
Amidine coordination allowed for the transmetallation (147), and reductive elimination process to 
obtain the uncyclized product (149). Under basic condition the CH3COOH is release leaving a 
free amine that will promote the nucleophilic attack to the amidine for the intramolecular 
cyclization of the benzimidazoles (143).      
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Figure 26 Proposed Cyclization of Amidines 
In 2009, Punniyamuthy
152
 took tri and tetra substituted guanidines expanding Batey’s 
cyclization reaction by using 5 mol% CuO nanoparticles with KOH, and DMSO as solvent (Figure 
27).  
 
Figure 27 Ligand-Free Copper-Catalyzed Cyclization of Amidines 
In this general study, it was possible to synthesize a wide number of Benzimidazoles and 
2-Aminobenzimidazoles with excellent yields going up to 97%. Extension of substrate scope also 
included a wide range of o-bromoaryl thioureas, and N-(o-bromophenyl) benzamides cyclized for 
the formation of 2-aminobenzothiazoles and benzoxazoles with high yields. 
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In 2009, Liu
87
 and Zhao that substituted 2-bromobenzoic acids could be used for the 
cyclization of amidines for the formation of quinazolinones. These compounds show hypnotic, 
anticonvulsant and antitumor activities.
153, 154
 It was shown that amidines as well as cyclic 
guanidines could undergo the cyclization process by using 10 mol% of copper iodide in presence 
of 1 equivalent of Cs2CO3 (Table 20).  
Table 20 Copper-Catalyzed Cyclization of Amidines 
 
An expansion of the substrate scope included guanidine substrates (entries 4 and 5). The 
reactions temperatures for these substrates were carried out at 80 °C to allow the formation of the 
product in moderate yields. Twenty one examples were shown to allow for formation of the 
quinazolinones in moderate to high yields. Some of the examples the substrate scope are shown 
in table 20. 
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Liu and Zhao proposed the mechanism for the copper-catalyzed reaction that involved 
the coordination of the copper to the carboxylic acid allowing for the formation of cesium iodide 
(Figure 28).  
 
Figure 28 Proposed Mechanism for the Formation of Quinazolinones 
 The reaction mechanism was followed by the transmetallation (156) step where the 
amidine coordinates with copper. The reaction conditions allowed the final cyclization (154) step 
in which water is displace to for the formation of the quinazolinones product. 
In 2010, Gong
133
 and collaborators showed that copper-catalyzed cyclization of amidines 
was possible for the formation of 2,4-disubstituted imidazolones using 2-bromolkylacrylic acids as 
starting materials (Table 21). These compounds show high antibacterial as well as potent GABAA 
receptor ligands. Reaction conditions allow for the development of a general methodology where 
5 different amidine salts were employed. Twenty two examples were shown employing the same 
reaction conditions. Some of the best examples obtained yields up to 94% are presented. Gong 
also proposed a mechanism for the formation of the 2,4-imidazolones which is similar to Liu’s 
mechanism for the formation of benzimidazoles in Figure 29. 
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Table 21 Copper-Catalyzed Cyclization of Amidines: Formation of 2,4-Disubstituted 
Imidazolones 
  
 
Figure 29 Proposed Mechanism for 2,4-disubstituted Imidazolones Formation 
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Gong proposed that the 2-bromolkylacrylic acids (158) will for a complex with the Copper 
Oxide in the oxidative addition step followed by addition of the amidine on the transmetallation 
step (162). The copper bromide leaves allowing for the reductive elimination (163) step to occur. 
The cyclization of the amidine allowed for the formation of the 2,4-disubstituted imidazolones on 
the final step (160).  
In 2011, Wei
155
 and Chen were trying to search for a greener Ullmann reaction conditions 
demonstrated that primary amines could be arylated by using catalytic amounts of copper 
powder.  Indeed, high temperatures and up to 12 hours reaction time were needed for this Ullman 
reaction. Figure 30 shows the reaction conditions that allowed the use water finding that no 
additives or bases were needed. 
 
Figure 30 Copper powder Catalyzed Ullman Reaction 
Control condition showed that air was indeed necessary for the reaction.  Thirty nine 
examples using methylamine, and a wide variety of aryl halides were used with yields up to 99%. 
Substrate scope included electron-donating and electron-withdrawing groups showing the 
versatility of this reaction conditions. The major drawback for this reaction was when other 
primary amines were used the reaction slowed down and the yield suffered as a result. 
3.3 Conclusions 
Copper-catalyzed reaction have been proved to be a useful reaction for a vide number of 
compounds that involves C-N bond formations.  Copper-catalyzed cross-coupling employing 
ligands and catalytic amounts of copper salts is used as an inexpensive alternative for Ullmann, 
Goldberg and palladium-catalyzed cross-coupling reactions. Recent development and 
improvements copper catalyzed cross coupling reaction have shown its versatility for medicinal 
and pharmaceutical application especially in the cross- couplings and cyclization of amidines and 
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guanidines for the formation of complex moieties. Examples and applications of copper catalyzed 
reactions shown previously are only a few of the most important in the C-N bond formations. 
Proposed copper-catalyzed cross-coupling mechanisms for the formation important medicinal 
compound were presented. Previous researches provided with vital information to have a better 
understanding of the different types of copper catalysis that can used to allow the access a 
variety of guanidine analogues.   
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CHAPTER 4 
 
SYNTHESIS OF SIGMA RECEPTOR LIGANDS 
4.1 Copper-Catalyzed Cross-Coupling: Guanidinylations 
Extensive research on Buchwald,
88, 131, 143, 156
 Deng,
149
 and Zhao’s
87
 were reviewed and 
taken the methodologies into account for the development of new copper-catalyzed cross-
coupling reactions. The main purpose of this research is to develop a methodology that can allow 
easy access of N,N’-di-substituted guanidines (169), using them as potential sigma receptor 
ligands for post stroke therapeutics. Glenon’s studies has been widely used as the model for the 
development sigma receptors.
39
 We followed this model for the development of the guanidine 
analogues having similar properties. 
Arylation of guanidines is not commonly found in the literature and represents a constant 
challenge, therefore our approach is to use an inexpensive available copper iodide to catalyzed 
cross-coupling of N,N’-disubstituted guanidines.  This straightforward methodology will make use 
of commercially available guanidine salts and aromatic halides as substrates.
157
 The use of 
copper iodide in catalytic amounts and a suitable ligand will provide with the opportunity to 
explore the viability of having a new route for the development of N,N’-disubstituted guanidine 
compounds as shown Figure 31.  
 
Figure 31 General scheme for the preparation of N,N’-disubstituted Guanidines 
We initiated our studies by exploring conditions that enable copper-catalyzed cross-
coupling using 1 mmol of each substrate at 2.0M, 10 mol% of CuI, 6 equivalent of base and 20 
mol% of commercially available N,N’-diethylsalicylamides (69) as a ligand (Table 22). The main 
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objective was to optimize the copper-catalyzed cross-coupling conditions by forming the already 
known sigma receptor agonist, N,N’-di-o tolyl guanidine (o-DTG) (1). Extensive solvent 
screenings found that double amination proceed in the presence of acetonitrile as the solvent 
(entry 13). Other coordinating solvents such as diethyl ether and THF, along with protic solvents 
such as ethanol ( average of two trials), resulted in conditions which produced low yields (Table 
22, entry 2, 6, and 7).  
Table 22 Optimization Conditions for the Copper Catalyzed Cross Coupling of 
Guanidines Nitrate with 2-Iodotoluene 
 
a.
The reaction used 1 mmol of guanidine nitrate and 1 mmol of 2-iodotoluene; Isolated yield.  
b
 CuBr was used in place of CuI. 
c
 Anhydrous CuCl was used. 
d
 No base was used.  
e
 No CuI was used. 
f.
0.2 M in substrate. 
g. 
Average of two trials. 
h.
 Average of three trials. 
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Toluene, dioxane, and DMF proved to be suitable solvents at higher temperatures, but 
again demonstrated in a low yield of the product (entry 1, 5, and 8). The solvents that showed 
reactivity had pka’s ranging from 23 to 41. Polar solvents with pka’s < 20 were not suitable for this 
reaction. Solvent pka’s ranging from 23 to 25 allowed the formation of the product in higher yields.  
Acetonitrile, with a pka of 25 is known to be a coordinating solvent, as well as, a labile ligand in 
many inorganic complexes making it a suitable solvent for the guanidinylation reaction. Having 
identified acetonitrile as the solvent of choice, it was found that at 80 °C, the reaction produced 
optimal yields. Lower or higher temperatures showed a decrease on yields (entries 10-12, 14). 
Other copper salts such as Copper Bromide and Copper Chloride were metal sources capable of 
catalyzing the reaction, but gave inferior results when compared to that of the Copper Iodide salt 
were found (entries 15 and 16). Control experiments conducted in the absence of ligand or base 
did not show any product formation (entries 17 and 18). 
A variety of ligands such as L2-L10 (Tables 23, entries 1-9) used in previous studies with 
copper were tested against N,N’-diethylsalicylamide (69) L1. For example, cyclohexane-1,2-
diamine (73a) L4 was used as a copper ligand and promoter of the double guanidinylation, albeit 
with inferior results (entry 3). To our surprise, our first ligand of choice, N,N’-diethylsalicylamide 
(69) L1 (entry 10), was the most suitable, allowing for the highest reactivity (92% yield). Softer 
bases such as K2CO3, Cs2CO3,(entries 11 and 12) with pka of the conjugate acid between 10 to 
13, and strong bases such KOt-Bu (entries 13) with a pka of the conjugate acid of 17 were 
studied, but resulted in no improvement in reactivity. When a strong base such as K3PO4 (pkb= 
1.6) was employed the reactivity of the reaction increased (entry 10). This also suggests that the 
right basic conditions are necessary for the success of the reaction.  
When the reaction concentration was increased from 0.2M to 0.4 M, a decrease of 
reactivity was observed (entry 16). Completion of optimization studies concluded the ideal 
reaction condition for the copper-catalyzed cross-coupling guanidinylation to be 1 mmol of 
guanidine nitrate, 1 mmol of substituted aryl iodide, 10 mol % CuI, 20 mol % of N,N’-
diethylsalicylamides, 6 equivalents of K3PO4, MeCN at 0.2 M, and 80 °C under an argon 
atmosphere for 24 hours.  
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Table 23 Ligand and Base Effect on Cross Coupling Reactivity 
a
.Reactions used 1:1 guanidine nitrate: 2-iodotoluene with a 0.2 M concentration. 
b.
 Isolated 
yields. 
c.
 Guanidine carbonate was used. 
d.
 Guanidine sulfate was used. 
e.
 The reaction was 
0.4 M in substrate. 
f .
 neat. 
g.
 Average two trials. 
h.
Average of three trials. 
 
When more than 1 equivalent of the aryl iodide is employed on the reaction, the tri-
arylated product is observed (Table 24). It is observed that the formation of disubstituted 
guanidine decreases with increasing equivalents of aryl iodides. The results from the copper 
catalyzed cross coupling reaction suggest that for double arylation to occur, it is necessary for the 
second arylation of the guanidines to occur at a faster than the first arylation.   
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Table 24 Optimization Reaction for the Double Arylation Control 
 
The results found for the formation of double arylated guanidines shows that the reaction 
occurs at a faster rate than the un-substituted guanidine substrates. Moreover, no monoarylation 
product was observed with these reaction conditions. After the first arylation occurs, the benzene 
ring is added to the guanidine (pka 13.7), helping to stabilize the resonance of the guanidine 
structure making it more reactive (pka <13.7); allowing the second arylation to occur even faster.  
The pka’s of typical di-substituted guanidines ranges from 10-13. 
In order to demonstrate the advantages of this catalytic system, we conducted reactions 
to study the electronic and the steric effects of the aryl halides (Table 25). The formation N,N’-di-
substituted guanidines was examined in the presence of an extensive substrate scope which 
found 2-iodotoluene (170) to be superior substrate giving the N,N’-di-o-tolyl guanidine (1) product. 
Substrate scope was extended to 3-iodotoluene and 4-iodotoluene resulting in the meta (172) 
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and para (173) disubstituted guanidines, giving moderate yields. The trend of reactivity of the 
guanidinylation for the methyl-substituted aryl iodides was ortho> meta> para (171-173).   
Table 25 Substrate Scope for the Formation of N,N-di-substituted Guanidines 
 
This reactivity trend does not follow Hartwig’s
158
 reactivity trends for the copper-catalyzed 
amination reactions. Hartwig observed that aryl iodides substituted by an electron donating group 
in the para position show higher reactivity. Substrates exhibiting more electron-donating effect 
such as o-methoxy (180) and m-methoxy (181) produced a decrease in yield, giving only 47% 
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and 20% respectively. Moreover, the ortho substituted methoxy aryl iodide demonstrated higher 
reactivity than meta substituted methoxy aryl iodide. Expanding the scope to aromatic substrates 
such as 2-naphtalene (177) and 1-naphthalene (178), substituted systems provided products in 
62 % and 50 % yield. This indicated that the low yields in the cross-coupling can be attributed to 
the steric hindering effect of the substrate’s substituents. When the less sterically hindered  
iodobenzene (176) is employed the yield increases to 83% yield. Disubstituted aryl iodides such 
as 2,4-dimethyl (179) promoted reactivity higher than those with mono-substitutions.  
Hartwig’s
158
 mechanistic studies on the Ullmann type amination employing 1,10-
phenantroline as a ligand, suggested that the copper catalyzed cross coupling reaction occurs 
with the formation of a Cu(III) intermediate, and not by a Cu(II) radical specie suggested by 
Strieter.
137
 Strieter suggested that the formation Cu(II) and Cu(III) intermediate may be dependent 
of the ligand, the temperature and the concentration of the Copper employed. Guo
142
 and 
collaborators also studied the arylation of amides by employing diamines using the density 
functional theory method to study the mechanism of Cu(I)-catalyzed aryl amidation. Their results 
of these studies suggested that diamine-ligated copper(I) amidate was the most reactive 
intermediate in the reaction mixture for the oxidative addition to aryl halide. Another catalytic cycle 
where the oxidative addition occurs first, followed by the nucleophile addition to form the Cu (III)  
specie has also been proposed.
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Based on Hartwig’s
158
 and Guo’s
142
 proposed mechanism, we proposed a similar 
mechanism for the copper-catalyzed guanidinylation. Copper (I) Iodide was employed as the 
catalyst and N,N’-diethylsalicylamide Ln, described by Kwong
128
 as an O donor ligand. The 
catalyst was used for the formation of the LnCu(I) species, having significant importance on the 
catalytic process (See Table 23). A hydrogen from the hydroxyl group of the N,N’-
diethylsalicylamide upon the presence of the base K3PO4. The deprotonated O from the N,N’-
diethylsalicylamides donates electrons to the copper. The catalytic cycle starts with the guanidine 
(nu) displacing the iodo followed by the oxidative addition of the aryl iodide forming the reactive 
copper (III) species. The reaction will proceed with the reductive elimination step by the formation 
of the arylated guanidine and the regeneration of the CuI to continue the catalytic cycle.  
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Figure 32 General Copper Catalyzed Cross Coupling Guanidinylation 
It was thought for our system that the donation of aryl iodide to the copper facilitates the 
oxidative addition (O.A.) step. It is believed that in the transmetallation step, the steric hindrance 
cause by the proximity of methyl group on the Cu (III)-guanidine complex reactive species will 
lead to formation of the desired product on the reductive elimination step. This does not follow the 
general trend that the electron-withdrawing containing substrates are better substrates with a 
faster reductive elimination step. 
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Additional expansion of the substrate scope showed the versatility of the copper-
catalyzed guanidinylation reaction (Table 26). It was observed aryl iodides with halogens 
substituents  exhibit stronger electron-withdrawing effects that still allowed for reactivity on the 
cross coupling reaction.  The reactivity trend showed that aryl iodides with fluorine substituents 
was that the para>meta>ortho positions gave (182-184) with 62%, 53% and 33% yield 
respectively.  
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Table 26 Substrate Scope for the Formation of N,N’-di substituted Guanidines. 
 
Halogen substitution of the para position showed an increase in yield in accordance with 
increasing electronegativity (184-186). Heteroaryl iodides, such as 3-iodothiophene (193), were 
good substrate for the guanidinylation reaction giving a 49 % yield. Moreover, disubstituted aryl 
iodides (194-195) were well tolerated with high yields. Cyano-substituted guanidines were also 
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achieved in low yields. The possibility of CN group of the aryl halide acts as a ligand prohibiting 
the oxidative addition by crowding the copper could also be another reason that lower yields 
(188,192) were obtained. 
For aryl halides bearing large electron-withdrawing groups such as chloro and bromo in 
the ortho position the reaction condition didn’t allow for the formation of the desired N,N’-di-
substituted product. The proper steric conditions, as well as electronic influences are necessary 
for the catalytic process to go forward. 
Understanding the physical properties of guanidine compounds is of interest to scientists. 
The solid and the solution properties of guanidines are known. Its dual ability as proton acceptor 
and -NH as proton donors is what makes a suitable candidate as sigma ligands. One of the 
properties studied was the pKa. N,N’-di-phenyl guanidine pka=13.0, which is very well known. The 
crystal structure of the N,N’-di-phenyl guanidinium salt
159
 shows it to have the highest stability 
when it has a “Y” shape; one of the aryl groups is down and the other is perpendicular and far 
away from the C=NH (Table 26).
160
 Further studies were performed to test the copper-catalyzed 
cross coupling guanidinylation reaction using N-methyl guanidine salt as substrates. Previous 
reports in the literature have demonstrated that tri-substituted guanidines containing a methyl 
group in one of the amines have affinity to sigma receptor.
57, 58
 With this thought in mind, 
development of these compounds could be useful as sigma receptor ligands for future 
evaluations. N-methyl guanidine salt (199) was used employing similar condition (Table 27). The 
optimized conditions for this reaction showed the difficulty of the double arylation when there is 
substitution on one of the amines of the guanidine with an electron donating group (CH3). Six 
examples (198-203) are showed form high electron-donating groups to highly electron-
withdrawing groups demonstrating that the double arylation is possible in low yields. The NMR 
13
C NMR data gathered provided information necessary to proposed that the structure is 
symmetrical having the methyl bonded to the nitrogen of the imine.  
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Table 27 Copper-Catalyzed Cross-Coupling for the Formation of Tri-substituted 
Guanidines 
 
Previous reports by Gopi
161
 showed similar, N,N’,N’’-tri-substituted guanidine crystal 
structures containing alkyl and aryl groups having the one substituted group per nitrogen. Gopi 
showed examples in which the orientation of the aryl groups were opposite in orientation to the 
imine.  
In conclusion, the copper-catalyzed cross-coupling reaction of guanidines with aryl 
iodides to form di and tri-substituted guanidines with moderate to high yields was discovered. By 
using mild and inexpensive reagents, we have successfully developed an efficient preparation of 
molecular entities based on a medicinally interesting parent compound, o-DTG (1). Developing 
other ways to create similar compounds containing similar chemical properties became the new 
focus.  New improved methodologies for development of monoarylated amidines were chosen to 
expand our library of compounds which would be evaluated with sigma receptor studies.  
54 
 
4.2 Ligand-Free Copper-Catalyzed Cross Coupling: Amidinylations 
 Having developed a new copper-catalyzed cross-coupling reaction suitable for the 
preparation of N,N’-disubstituted guanidines (169), it was now necessary to go forward 
investigating other structures that potentially possess similar characteristics. Previous research 
had found that monoarylated amidines were used as guanidine mimics as calcium channel 
blockers.
90
 These moieties could provide additional structural activity relationship for the 
development of sigma receptor therapeutic drugs for ischemic stroke.  
Deng
149
 et. al demonstrated that it was possible to trap the monoarylated amidines 
intermediate on the copper-catalyzed cyclization for the formation of benzimidazoles . Our goal 
was to develop a straightforward arylation procedure utilizing substituted aryl iodides and 
commercially available amidine or benzamidine salts for the formation of N’-arylated amidines 
and N’-arylated benzamidines.
162
 The use of catalytic amounts of copper iodides and a base are 
essential for the reaction to go forward as showed in Figure 32. 
 
Figure 33 Amidinylation Reaction using Aryl Iodides and Amidine Salt 
During the onset of our exploration of copper-catalyzed conditions for amidine arylation, it 
was found that typical copper ligands employed for arylation of amides, amines or guanidines did 
not provide for rate acceleration. Ligand-free conditions that enable the copper-catalyzed reaction 
used benzamidine salt, aryl iodides, and CuI (Table 28).  
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Table 28 Copper-Catalyzed Conditions for the Synthesis of N-Tolyl Benzamidine 
 
Several of the previous solvents that showed reactivity toward the guanidinylation
157
 
reaction were employed for the formation of monoarylated amidines.
162
 Of the solvents 
investigated (entries 1-5) the reaction was found to proceed efficiently in DMF giving 28%. 35%, 
59% and 89% yields in 4, 8, 16 and 24 hours respectively.  Additionally, it was confirmed that 2 
equivalents of Cs2CO3 was ideal. Cesium was used as the main base since it has been 
previously employed in cyclization of amidines When the amount of Cs2CO3 was decreased 
(entry 6 and 7) or increased (entry 8-10), a dramatic lowering of yield was observed.  It is 
speculated that additional base could cause catalytic inhibition, leading to lower yield.  Evaluation 
of additional bases such as K3PO4, K2CO3, and KOt-Bu (entries 11-13) provided conditions that 
gave a much lower yield of the arylation product relative to Cs2CO3.  
After the optimization of the copper-catalyzed cross coupling amidinylation was 
completed, a substrate scope was developed. Table 29 presents a summary of results varying 
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sterics and electronics on the aryl iodide reactants. 2-Iodotoluene was an excellent substrate, 
providing the N-o-tolylbenzamidine (208) in very high yield. Substrate scope was extended to 
include 3-iodotoluene and 4-iodotoluene, obtaining the meta (209) and para (210) monoarylated 
benzamidine in moderate yield.  
Table 29 Ligand-Free Copper-Catalyzed Cross Coupling of Benzamidines 
 
The reactivity trend for the methyl-substituted aryl iodides was found to be 
ortho>meta>para. We explored substrates with a stronger electron-donating effect, such as o-
methoxy (212) and found a decrease in yield to 55% when compared to o-methyl (207), as well 
as, a drastic decrease in reactivity when iodobenzene (217) was used. It was observed that for 
methoxy in the meta (213) and the para (214) position reactivity decreased with lower yields 
compared to the ortho (212) position. Sterically hindered substrates showed good reactivity, 
demonstrating that the arylation is possible even in cases where steric hindrance is increased 
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(218-219). Also was shown that 2-iodopyridine was achieved in high yield (220) and heterocycles 
such as 3-iodothiophene was also tolerated (221).   
Table 30 presents the expansion of the substrate scope which shows that the reaction 
proceeds in moderate to high yields when electron-withdrawing groups were employed (222-233). 
Disubstituted aryl iodides (237-240) were also evaluated in the chemistry and provided for 
moderate to high yields of the arylation product.  
Table 30 Substrate Scope for the Formation of Monoarylated Benzamidines 
 
A general trend of reactivity for the aryl halides in the para substituted position followed: 
F>Cl>Br. cyano, nitro, trifluoromethyl and O-trifluoromethyl were some the compounds tested for 
the substrate scope achieving moderate yields. 
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We proposed the following catalytic cycle for amidines based on Hatwig’s
158
 and Guo’s
142
 
studies previously discussed for the guanidinylation cycle. This catalytic cycle starts  by the 
displacement of the iodo of the copper (I) iodide by the amidine to form a Cu-amidine complex.  
This step is followed by the oxidative addition of the aryl iodide forming a copper (III) reactive 
species.  The reductive elimination as the final step will allow the formation of the mono-
substituted amidine. 
 
Figure 34 Proposed Catalytic Cycle for the Formation of Amidines 
 
Additional studies were performed to demonstrate how the arylation method can be 
applied to a wide variety of amidine moieties (Table 31). It is noticeable that the highest reactivity 
was found when employing benzamidine salt (entry 1) with 84% yield. Benzamidine salts bearing 
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electron-withdrawing groups (entry 2) or electron-donating groups (entry 3) were well tolerated. It 
was also observed that isoniconamidine hydrochloride can also be arylated, albeit with lower 
chemical yield (entry 5). Bulkier amidines also tolerated, but with lower reactivity (entry 6). 
Table 31 Expansion of Amidine Substrate Scope 
 
After determining which amidine substrate provided the best reactivity, m-Nitro-
benzamidine salt was chosen to continue our substrate scope. These substrates were selected to 
be tested for sigma receptor response against o-DTG. As it seems in the benzamidine cases, 
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there is no reactivity relationship when comparing o-methyl (238) and p-methyl (246) substituted 
aryl iodides (Table 32). In this case, the highest reactivity is for the p-methyl (246) substituted aryl 
iodide with 85%, which does not follow guanidine or benzamidine reactivity trends. It was also 
observed that for the non-substituted iodobenzene (247) the reactivity reach its highest with 98% 
yield. 
Table 32 Substrate Scope for m-Nitrobenzamidine salt 
 
Fluorine substituted aryl iodides were chosen due to their previous observed moderate 
reactivity in the arylation conditions that were developed presenting moderate reactivity (248, 
249). Moreover, the p-bromoiodobenzene (250) was chosen to compare its reactivity with the p-
methyl-iodobenzene (246). It was noticed that the electron-donating group at the same position 
showed higher reactivity with 85% yield compared to the electron-withdrawing groups with 54% 
yield. Due to the steric hindrance caused by the extension of aromaticity , the reactivity for this 
reaction shows lower yields (251).  In general, the electron-donating group, methyl showed higher 
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activity for the copper-catalyzed cross- coupling that any other electron-withdrawing groups with 
this reaction conditions. 
Additional expansion of substrate scope was explored to examine the reactivity of 
amidine salt as substrate (Table 33). In this case, the only deviation from the reaction condition 
was the use of acetonitrile as the solvent. The arylation with electron-donating groups present 
tolerates the reaction conditions allowing for a moderate to high yields of the monoarylated 
product. When using iodobenzene (255), the highest yield (84%) was found for the amidine 
arylation. The disubstituted aryl iodides and strong electron-withdrawing groups tolerated the 
reaction conditions and afforded moderate yields (257-259). 
Table 33 Substrate Scope for Amidine Salt 
 
It was found in previous research that isonicotinamidines (263) demonstrated anti-
inflammatory activity.
86
  Moreover, studies have showed that replacing nitro groups in a benzene 
ring for a pyridine isothere decreases the toxicity of similar compounds, and for this reason it was 
thought that these compounds could be useful as potential drug candidates in post stroke 
therapy.
163
 This general methodology provided easy access of these types of moieties.  It is 
clearly seem that the addition of a nitrogen group in the ring diminished the reactivity of the 
amidine toward the copper-catalyzed cross-coupling reaction (Table 34). Electron-donating (241), 
as well as, electron-withdrawing groups (265) were employed providing with low to moderate 
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reactivity. Extension of aromaticity from 2-iodotoluene (264) to 1-iodonaphthalene (266) 
decreases the reactivity by more than a half due to an increase in steric hindrance. 
Table 34 Isonicotinamidine Salt Substrate Scope 
 
The copper-catalyzed cross-coupling amidination reaction is similar to the ones proposed 
in previous literature by Zhao and Deng. 
149
 Furthermore, we have developed a general method 
for the synthesis of mono-substituted amidines using ligand-free copper-catalyzed protocol. By 
using mild conditions and inexpensive reagents we have successfully developed a procedure to 
prepare a number of arylated amidines in moderate to good yields that could be used as potential 
compounds for evaluation as ischemic stroke therapeutics.  
4.3 Formation of Carbamides: C-N bond by Peptide Coupling Agents 
It was our interest to expand the library with other methodologies that could allow easy 
access to guanidine analogues to be used as potential candidates for ischemic stroke 
therapeutics.  Recent studies suggest that carbonyl containing compounds could be used as 
possible sigma-1 receptor ligands.
164
 Previous research showed that condensation of carboxylic 
acid with amidines
111
 was an useful methodology for the formation of carbamides employing 
HATU
112, 113
 as the coupling agent.  Exploring similar methodology for the formation of N,N’-di-
subtutituted carbamides became our next goal. Starting materials such as guanidine nitrate and 
different substituted carboxylic acids and furoyl acids were employed (Figure 33). The reaction 
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conditions used were similar to the one found in previous research hoping that this reaction would 
form the desired product.  
 
Figure 35  General Scheme for the Formation of N,N’-disubstituted Carbamides 
During the initial phase of our exploration of condensation reaction conditions, we found 
that the typical reaction conditions used for the amidine condensation reported by Castanedo and 
collaborators allowed for the formation of the N,N-di-substituted carbamides.
111
  The reaction 
conditions began with a base effect keeping the guanidine nitrate to carboxylic acid ratio 2:1. The 
general trend shows that at a 0.25M concentration there is an increase in the yield with decrease 
of base. When the substrate ratio was 1:1, the general pattern showed that with an increase of 
there was an increase in the yield (Table 35).  
Table 35 Base Effect Studies for Condensation Reaction 
 
Maintaining the substrate ratios, and decreasing or increasing the reaction concentration 
did not have a positive effect on the yields.  The highest yield (86%) was achieved when 1 
equivalent of guanidine nitrate, 1 equivalent of carboxylic acid, 1 equivalent of HATU, 7 
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equivalents of DIPEA in 0.2M DMF at room temperature. The substrate scope for the carboxylic 
acids included a wide variety of electron donating and electron withdrawing groups  (Table 36). 
When a stronger electron donating group such as methoxy (273) is located on the para position, 
its reactivity decreases and a 73% yield is obtained.  Similar reactions were performed by 
employing I, Br, and F substituted in the para position showing that the general reactivity pattern 
is F > Br> I with 72%, 60%, and 54% (276-278) respectively.   
Table 36 Substrate Scope for the Formation of N,N'-di-substituted Carbamides 
  
This pattern could be explained by the electronegativity of the halogens.  The more° 
electronegative halogen the less electron dense the carbonyl will be, this will make it more 
reactive toward the condensation. Reactivity for the disubstituted (281) carboxylic acids highly 
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increases when a methyl is in the ortho position with a 97% yield. Overall 13 examples with 
moderate to excellent yields were synthesized. Moreover, other substrates were also explored, 
due to their biological activity as nicotinic ligands (Table 37).  
Table 37 Formation of N,N’-disubstituted Furoyl Guanidines 
 
The formation of N,N-substituted furoyl guanidines was also tested. Two of the main 5’-
substituted furoyl guanidines compounds that showed previous activity were synthesized. This 
methodology provided higher reactivity than previous used for the formation of these substrates. 
Four examples were successfully made with yields up to 95%. Replacement of furoyl group with a 
thiophene group lowered the reactivity of the reaction. It is noticeable that an addition of a methyl 
substituent (285) in the furoyl 5’ position showed lower reactivity compared to the unsubstituted 
furoyl (284).  
A representative example for the peptide-coupling mechanism employing HATU as the 
peptide coupling agent is as showed in Figure 34. The mechanism for this reaction starts with the 
deprotonation of the benzoic acid by DIPEA followed by the attack of the deprotonated benzoic 
acid to the imine of the HATU. This leads to the formation of an ester-intermediate, which later on 
is broken by the negatively charge of the HATU. The guanidine substrate will hydrogen bond with 
the nitrogen of the HATU aromatic ring of the promoting the final condensation reaction that leads 
to the product. For this process formation of the monosubstituted product was not observed. This 
leads to believe that the nature and the reactivity trends of the guanidines in most cases studied 
promotes the formation of substituted guanidine by double coupling, as its most preferred form. 
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Figure 36 Peptide-Coupling Mechanism 
We have developed a general method for the synthesis of N,N’-disubstituted carbamides. 
By using the peptide coupling agent with mild conditions and inexpensive reagents we have 
successfully developed a procedure to prepare a number of symmetrical N,N’-di-substituted in 
moderate to good yields that could be used as potential compounds for evaluation as ischemic 
stroke therapeutics. 
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CHAPTER 5 
 
Structure Affinity Relationship of Sigma Receptor Ligands 
 
5.1 Introduction 
After the synthesis and characterization of various guanidines analogues by copper-
catalyzed cross coupling reactions, it was our next goal to evaluate the compounds for Sigma 
Receptor Response. Evaluation studies of the analogues for sigma receptor response were 
performed at the Department of Molecular Pharmacology and Physiology Department at Dr. 
Javier Cuevas Laboratory under the guidance and collaboration of Adam Behensky and Chris 
Katnik. Cortical neurons from embryonic (E-18) Sprague-Dawley rats (Harlan, Indianapolis, In) 
were used for the evaluation of the guanidine analogues. The preparation of the cortical neurons 
was performed by using the procedure previously described by Katnik
17
 and collaborators. The 
prepared cortical neurons were used between 10 to 21 days.  
5.2 Procedure 
Ratiometric fluorometric calcium imaging was used to measure the changes in 
intracellular calcium concentration. The poly-lysine coated coverslips containing the cortical 
neurons cells were incubated for 1 hour at room temperature in Neurobasal medium containing 3 
μg/mL of the acetoxymethylester form of Fura-2 (Fura-2 AM) and 0.3% DMSO. Coverslips were 
rinsed in physiological saline solution (PSS) containing: 3 mM KCl, 140 mM NaCl, 7.8 mM 
glucose, 2.5 mM CaCl2, 10 mM HEPES and 1.2 mM (pH to NaOH).  For the acidosis, the PSS 
solution contained: 140 mM NaCl, 4.5 mM KCl, 25 mM HEPES, 20 mM glucose, 1.3 mM CaCl2 
and 1.0 mM MgCl2 (pH 7.4 with NaOH). The respective PSS solutions were used as control 
solution in all the experiments and drugs were delivered onto the cortical neuron using equipment 
described by Cuevas.
165
 The procedure to performed ischemia described by Katnik
17
 employed a 
glucose –free PSS solution containing 4 nM NaN3. The acidosis procedure described by 
Herrera
22
 used a PSS solution with a pH 6 to mimic the acidic environment of the cell. All 
68 
 
guanidine analogues were applied in PSS for 10 min prior to and during the ischemia or acidosis. 
Data analysis and evaluation studies were performed on the following guanidine analogues: o-
DTG, m-DTG, p-DTG, DPhG, o-FDPHG, m-FDPhG, and p-FDPhG, o-ClDPhG, m-ClDPhG, p-
ClDPhG, o-BrDPhG, m-BrDPhG, p-Br-DPhG. o-BrDPhG and o-ClDPhG were synthesized 
according to Reddy’s procedure.
58
  Fluorescence intensities were recorded from the cortical 
neurons as previously described Katnik
17
 and Herrera,
22
.  
Once the data was gathered, the final data analysis was performed by Adam Behensky 
using SigmaPlot/SigmaStat 11 (Systat Software, Inc. San Jose, CA). Data points represent peak 
means ± standard error of the mean (S.E.M.). Paired and unpaired Student’s t tests were used to 
determine significant difference within- and between-groups, respectively. Results were 
considered statistically significant if p < 0.05. One- and two-way variance analysis was used to 
determine significant differences for multiple group comparisons followed by post hoc analysis 
using either a Tukey or Dunn’s Test. The following equation was used to calculate the Mean 
relative inhibition: 
Mean Relative Inhibition =   
   
 
[
     
 
]
 
where  
C =control response,  
X=response in the presence of the test compound, 
DTG= the response in the presence of o-DTG. 
5.3 Data Analysis for the Structure Affinity Relationship  
Evaluation of Sigma Receptor Response was fully performed for the halide substituted 
guanidines in the ortho, meta and para position. Table 38 presents the values obtained for the 
Mean of Relative Calcium Inhibition for each compound at 100 μM for ischemia and acidosis. The 
values were compared to the values of o-DTG. The mean relative inhibition for both tests was o-
DTG =1.00. A value greater than 1.00 in both test indicates that the compound ability of 
decreasing calcium elevation during an ischemic stroke. 
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Table 38 Mean of Relative inhibition of Calcium for Ischemia and Acidosis for N,N-
disubstituted Guanidine 
 
The results of these studies were necessary to determine which drugs were suitable 
candidate for ischemic stroke therapy. The N,N’-disubstituted compounds that showed positive 
significant difference from o-DTG for both tests were: m-ClDPhG, p-ClDPhG, m-BrDPhG, and p-
BrDPhG. Moreover, it was observed that for the efficacy trend for the relative inhibition of calcium 
for the para substituted guanidines in both tests was: Br> Cl> F. It is a fact that Bromo and Chloro 
containing compounds have a better permeability to the cell membrane. Ortho fluoro was the only 
halogen-substituted compound that showed significant difference compared to o-DTG for the 
NaN3 study. Studies found in the literature suggested that the hydrogen bonding ability of fluorine 
in the ortho position leads to conformational changes in the structure increasing its membrane 
permeability.
163
 Additionally, replacing hydrogen to a fluorine reduces the basicity of the proximal 
amines.
163
  In this case, the higher size of the halogen atom on the molecule, the higher the 
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efficacy. It was also noticeable that when comparing mean values for relative inhibition of o-DTG 
with the values DPhG, DPhG shows higher efficacy in decreasing the calcium elevation.  
Since the bromine compounds demonstrated the highest efficacy to decrease the calcium 
elevation during ischemia and acidosis, a structural/activity relationship was performed. The 
bromo-substituted guanidines were studied based on sterics. An example how the inhibition of 
calcium influx of induced ischemia with sodium azide (NaN3) for ortho, meta and para positions of 
the bromo-substituted guanidine compared to the control (o-DTG) is showed (Figure 35).  
 
 
Figure 37 Inhibition of Calcium Elevation of Induced Ischemia from ortho, meta and 
para BrDPhG 
The general efficacy trend for these substrates found was that the farther away from the 
guanidine core a higher calcium inhibition is observed. The efficacy trend for the bromo- 
substituted guanidines is a follows: para>meta>ortho.  All of the compounds exhibit higher 
calcium inhibition than o-DTG, but m-BrPhG and p-BrDPhG were significantly different 
demonstrating a 20% (m-BrDPhG) and 25% (p-BrDPhG) higher inhibition than o-DTG.  
An additional panel of how sigma receptors could directly influence inhibition of calcium 
influx during acidosis (pH=6) is showed in Figure 36. The panel shows inhibition of calcium influx 
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of induced acidosis at a pH= 6 for ortho, meta and para positions of the bromo-substituted 
guanidine compared to the control (o-DTG). 
 
 
Figure 38 Calcium Inhibition by Induced Acidosis for ortho, meta, and para BrDPhG 
A similar trend was observed for calcium inhibition by induced acidosis. The efficacy 
trend for the bromo- substituted guanidines is as followed: para>meta>ortho. All of the 
compounds exhibit higher calcium inhibition than o-DTG, but m-BrPhG and p-BrDPhG were 
significantly different demonstrating a 20% (m-BrDPhG) and 25% (p-BrDPhG) higher inhibition 
than o-DTG. Additional studies performed by Adam Behensky found that the o-DTG IC50=74.7μM 
and p-BrDPhG IC50=2.2 μM showing that p-BrDPhG is more potent than o-DTG. 
In conclusion, the structure/affinity relationship shows the capacity of para substituted 
compound were the most efficacious and more potent in inhibiting the calcium elevation during 
ischemia and acidosis than o-DTG. The results suggest that p-Bromo containing guanidines have 
the potential of becoming to become drug candidate for post-stroke therapeutics.  
5.4 Middle Cerebral Arterial Occlusion 
The Middle Cerebral Arterial Occlusions were performed by Dr. Keith Pennypacker’s 
Laboratory at the Department of Molecular Pharmacology and Physiology-College of Medicine. 
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Lisa Collier and Craig Ajmo
20
 were responsible for conducting the strokes studies.  For these 
tests the rats underwent surgery for permanent middle cerebral arterial occlusion (MCAO). Rats 
received subcutaneous injections 24hr post-surgery; 7.5 mg/kg N,N-di-p-bromophenyl guanidine 
(p-BrDPhG) or N,N’-di-o-tolyl guanidine (DTG). Subsequent injections were given at 48 and 72 
followed by euthanasia at 96 hours. Fixations of the brains were performed using Fluoro-Jade 
fluorescence to determine infarct volume. 
 
Figure 39 Evaluation of p-BrDPhG and o-DTG using Middle Cerebral Arterial Occlusion 
The values of the percentage of Infarct Volumes from p-BrDPhG and o-DTG were 
compared to the MCAO of untreated rats. After sections of the brain were examined, it was found 
that p-bromophenyl guanidine (p-BrDPhG) significantly decreased the infarct volume by more 
than 55% compared to the MCAO (Figure 38). The results suggested that p-BrDPhG decreases 
the infarct volume with higher efficacy than o-DTG. The information found on the sigma receptor 
response tests and the MCAO showed that p-BrDPhG is a potential candidate for ischemic stroke 
therapy.  
5.5 Molar Solubility Tests 
 N,N’-di-p-bromophenyl guanidine (p-BrDPhG) was found to be the compound that shows 
the most significant difference compared to N,N’-di-o-tolyl guanidine (o-DTG)  in the inhibition of 
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calcium during induced ischemia and acidosis. Our laboratory was interested to determine 
soluble was p-BrDPhG in water compared to o-DTG at a pH 7.4 (biological pH). A molar solubility 
test was performed with the guidance and support of Jordany Maignan a graduate student 
researcher in the laboratory of Dr. Roman Manetsch at the University of South Florida. Protocol 
for the molar solubility is showed below. Instrumentation used for this experiment was LC-MS 
Agilent Technology 1100 series from Dr. Roman Manetsch Laboratory. 
5.5.1 Protocol: Making the Calibration Curve Plate 
An initial stock solution for each of the test compounds was made at a concentration of 
10mM. A 96 well plate was prepared by adding 200µL of the stock solution to the well plates in 
row A, columns 1 thru 12. Next, a serial dilution was performed in the well plates in rows B thru H, 
columns 1 and 2 as follows:  A 20µL aliquot of the compound test solution in well plate A1 was 
pipetted with a micro-pipette into well plate B1. This was followed by the addition of 180µl of 
DMSO for a total final volume of 200µl in well plate B1. Subsequently, 20µL from well plate B1 
was pipetted by micro pipette and introduced into well plate C1. Yet again, 180µL of DMSO was 
added to well plate C1 for a final volume of 200µL in well plate C1. This process was continued 
until well plates in rows B thru H, columns 1 and 2 were filled with 20µL aliquots originating from 
the preceding well plate and completed to a volume of 200µL with DMSO.  
5.5.2 Plotting the Calibration Curves 
Using the UV spectra obtained from the Agilent Technology 1100 Series LC-MS allowed 
for the analysis of the eight observed concentration peaks. Peak integration was obtained using 
the ACD/MS Manager software from Advanced Chemistry Development, Inc. which is included 
with the instrument. A plot of the peak area versus the concentration was generated using 
Microsoft Excel 2010 displaying a trend line with a y-intercept of 0. 
5.5.3 Making the Solubility Plate 
An initial stock solution for each of the test compounds was made at a concentration of 
10mM. To a 96 deep-well plate add 597µL of Dulbecco's Phosphate-Buffered Saline (DPBS) 
pH=7.4. The well plates were charged with 6µL of the 10mM test compound stock solution and 
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allowed to sit at room temperature for 18 hours. The solutions were filtered using Beckman-
Coulter CBD-V Solution Filtration Instrument and collected into a 96 storage well- plate and then 
placed into a 96 deep-well plate.  
5.5.4 Data Interpretation 
Using the aforementioned data gathered from the calibration curve analysis, the 
concentration of each compound was found using the slope of the calibration curve trend line. 
The mean and the standard deviation were able to be calculated as well.  Compounds not 
observed by UV may be analyzed using MS and a calibration curve and solubility calculations can 
be obtained from this data.  
5.5.5 Results 
The o-DTG test concentration in DMSO started at 1000 μM to 15.6 μM. The Table 39 
showed the integration under the curve for each of the o-DTG concentrations in DMSO.  The 
peak areas from the LC-MS were taken into consideration where those in which the area under 
the curve was symmetrical. 
Table 39 Peak Area vs Concentration of o-DTG in DMSO 
o-DTG Concentration (μM) Peak Area 
A 1000.0   
B 500.0   
C 250.0   
D 125.0 361.3 
E 62.5 147.7 
F 31.4 69.7 
G 15.6 35.9 
      
Slope   2.7531 
 
With the data provided on table 39, a calibration curve was obtained, showing the Peak 
Area versus Concentration of N,N’-di-o-tolyl guanidine (o-DTG) at biological pH (7.4).  The linear 
equation was found to be equal to y=2.753x. The value of the slope of the line is necessary to 
determine the concentration of o-DTG in water (Figure 37). 
 
75 
 
 
Figure 40 Peak Area versus Concentration of N,N’-di-o-tolyl guanidine 
The average of the four peak areas for o-DTG was calculated and found to be 386.2 
(Table 40) and the slope of the line 2.7531, according to the line equation used to calculate the 
concentration of o-DTG. The molar solubility of o-DTG in water was found to be >100 μM which is 
a larger value than 20μM. Twenty is the accepted value to determine if a compound is suitable to 
continue for additional biological testing for drug candidates. 
Table 40 Concentration of o-DTG in Water 
o-DTG Sol_1 sol_2 sol_3 Sol_4 Average 
Peak Area 460.5 416.5 342.3 325.6 386.2 
 
The N,N’-di-p-bromophenyl guanidine (p-BrDPhG) concentration in DMSO chosen was 
between 1000 μM to 7.8 μM. The Table 41 showed the integration under the curve for each of the 
p-BrDPhG concentrations in DMSO at pH 7.4. The peak areas taken in consideration were those 
in which the area under the curve was symmetrical. 
  
y = 2.7531x 
R² = 0.9812 
0
50
100
150
200
250
300
350
400
0 20 40 60 80 100 120 140
P
e
a
rk
 A
re
a
 
Concentration (μM) 
Peak Area vs Concentration  of  N,N'-di-o-tolyl guanidine  in 
DMSO at pH 7.4   
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Table 41 Peak Area vs Concentration of p-BrDPhG in DMSO 
p-BrDPhG Concentration (uM) Peak Area 
A 1000.0   
B 500.0   
C 250.0 6853.4 
D 125.0 3350.5 
E 62.5 1376.4 
F 31.2 566.9 
G 15.6 258.1 
H 7.8 125.8 
      
Slope   26.898 
 
With the data provided, a calibration curve was obtained showing the Peak Area vs 
Concentration of N,N’-di-p-bromophenyl guanidine (p-BrDPhG) at biological pH 7.4 (Figure 38).  
The linear equation was found to be equal to y=26.898x. The value of the slope of the line is 
necessary to determine the concentration of p-BrDPhG in water.  
 
 
Figure 41 Peak Area vs. Concentration of p-BrDPhG in DMSO 
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The average of the four peak areas for p-BrDPhG was calculated and found to be 3020.7 
(Table 42) and the slope= 26.898, according to the line equation used to calculate the 
concentration of o-DTG. The molar solubility of o-DTG in water was found to be >100 μM, Again 
this value is a larger than 20 μM, an accepted value which determines if a compound is suitable 
for additional biological testing for drug candidates. 
Table 42 Molar Solubility for p-BrDPhG in Water 
p-BrDPhG Sol_1 Sol_2 Sol_3 Sol_4 Average 
Peak Area 2927.9 2929.7 3087.4 3137.6 3020.7 
 
5.5 Conclusion 
The data analyses performed found the molar solubility in water at pH 7.4 for both o-DTG 
and p-BrDPhG. These molar solubility values strongly show that both compounds warrant further 
testing as drug candidates for ischemic stroke therapeutics.  These results also suggested that not 
only the physical properties, but the chemical interactions with the sigma receptor are important 
factor for the development of stoke drug candidates.  
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CHAPTER 6 
 
EXPERIMENTAL PROCEDURES 
 
6.1 General Information 
All reactions were carried out in flame-dried screw cap test tubes with magnetic stirring. 
Reactions were run under an inert atmosphere of argon gas. The reaction solvent, toluene was 
purified by passing through a column of activated alumina under a dry argon atmosphere. Copper 
Iodide, substituted aryl iodides, anhydrous dioxane, anhydrous acetonitrile, anhydrous 
dimethylformamide (DMF), carboxylic acids, N’N’-di-isopropyl ethylamine (DIPEA) and potassium 
phosphate tribasic were purchase from Sigma Aldrich. N,N’-diethylsalycilamide was purchased 
from Sigma Aldrich and used after standard purification by crystallization, or prepared by a known 
literature procedure.
158
. The reaction solvent, toluene was purified by passing through a column 
of activated alumina under a dry argon atmosphere. Cesium carbonate (99.99%) was purchased 
from Chemetall. Peptide coupling agents were purchase from Oakwood Scientific. Thin layer 
chromatography was performed on Merck TLC plates (silica gel 60 F254). Flash column 
chromatography was performed with Merck silica gel (230-400 mesh). Column conditions are 
reported in the experimental section below. Melting points were determined using a MEL-TEMP 
3.0 instrument and are uncorrected. 
1
H NMR and 
13
C NMR were recorded on a Bruker Advance 
DPX-250 (250 MHz) instrument and Varian 400 MHz with chemical shifts reported relative to 
Chloroform (CDCl3) and Methyl sulfoxide (DMSO-d6). The HRMS data were measured on an ESI/ 
TOF or MSD/TOF mass spectrometer with electrospray ionization.  
6.2 Experimental Procedure Chapter 4, Section 4.1 
General procedure for preparation of N, N’-di-p-bromophenyl guanidines:
162
  
To a screw-cap reaction tube was added guanidine nitrate (1 mmol, 0.1221 g), 1-bromo-
4-iodobenzene (1 mmol, 0.2840 g), CuI (0.1 mmol, 0.190 g), N,N’-diethylsalycilamide (0.20 mmol, 
0.386 g), and K3PO4 (1.2778 g, 6 eq.). The reaction tube was placed under high vacuum and 
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backfilled with Argon and repeated three times. Toluene (5 mL) was added using a syringe and 
the mixture was heated to the desired temperature with use of an oil bath. After the resulting 
solution was stirred for 24 hours, the product was extracted using dichloromethane, washed with 
water 3 times, and the organic layer was dried over anhydrous Na2SO4. Following concentration 
under reduced pressure, the residue was purified by silica gel chromatography (4:1:0.25 to 
4:1:0.75 EtOAc: Hexanes: Et3N) = to afford the desired product.  
Reference 
1. U.S. Patent: #4,898,978 by Bergfeld et.al. in 1990. 
 
N,N’-di-o-tolyl guanidine (o-DTG) (1)
 1,58
: Following the general procedure the product 
was obtained by silica gel chromatography (hexanes: EtOAc: NEt3 = 1:4:0.025 to 1:4:0.075, Rf = 
0.37) to give N,N’-di-o-tolyl guanidine as  a white solid, 112.6 mg, 92 % yield. Mp: 175.4 - 176.0 
°
C. 
1
H NMR (250 MHz, DMSO-d6): δ 2.23(s, 6H), 5.23 (s, 2H), 6.91-6.83 (m, 2H), 7.11 (m, 5H), 
7.49 (br, s, 2H). 
13
C NMR (62.5 MHz, CDCl3): δ 152.87, 143.55, 133.80, 131.70, 127.74, 126.15, 
125.29, 18.24. MS (ESI): C15H17N3 Calcd. for ([M+H]
+
) 240.2, found 240.2. 
 
N,N’,N’’-tri-o-tolyl guanidine (o-TTG) (1a):
1
 Following the general procedure the 
product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:4:0.025 to 
1:4:0.075, Rf = 0.40) to give N,N’,N’’-tri-o-tolyl guanidine as  a cream solid. Mp: 192.4 - 194.0 
°
C. 
1
H NMR (250 MHz, DMSO-d6) δ 7.47 (d, J = 6.9 Hz, 3H), 7.16 (dd, J = 17.1, 7.6 Hz, 6H), 6.94 (t, 
J = 7.2 Hz, 3H), 6.31 (s, 2H), 2.24 (s, 9H).
 13
C NMR (63 MHz, DMSO-d6) δ 148.66, 142.47, 
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130.13, 129.48, 126.24, 122.60, 122.17,17.9. MS (ESI): C22H23N3 Calcd. for ([M+H]
+
) 331.0, 
found 331.0. 
 
N,N’-di-m-tolyl guanidine (m-DTG) (172):
1
 Following the general procedure the product 
was obtained by silica gel chromatography (hexanes: EtOAc: NEt3 = 1:4:0.025 to 1:4:0.075, Rf = 
0.21) to give N,N’-di-m-tolyl guanidine as white solid, 40.5 mg, 66 % yield. Mp: 105.0 - 106.0
 °
C.  
1
H NMR (250 MHz, CDCl3): δ 2.29 (s, 6H), 5.12 (br, s, 3H), 6.90 (q, J = 7 Hz, J = 22 Hz, 6H), 7.18 
(t, J = 9 Hz, 2H).  
13
C NMR (62.5 MHz, CDCl3): δ 149.84, 143.93, 139.23, 129.17, 123.94, 123.75, 
119.90, 21.42. MS (ESI) C15H17N3 Calcd. ([M+H]
+
) 240.2, found 240.2. 
 
N, N’-di-p-tolyl guanidine (p-DTG) (173):
1
 Following the general procedure the product 
was obtained by silica gel chromatography (hexanes: EtOAc: NEt3 = 1:4:0.025 to 1:4:0.075, Rf = 
0.44) to give N, N’-di-p-tolyl guanidine as a white solid, 13.9 mg, 49 % yield. Mp: 129.2 - 130
 °
C. 
1
H NMR (250 MHz, CDCl3): δ 2.23 (s, 6H), 4.98 (br, s, 3H), 6.99 (d, J = 8.3 Hz, 4H), 7.09 (d, J = 
8.1 Hz, 4H). 
13
C NMR (62.5 MHz, CDCl3): δ 150.04, 132.88, 130.00, 123.27, 100.01, 20.83. MS 
(ESI) Calcd. for C15H17N3 ([M+H]
+
) 240.2, found 240.2. 
 
N,N’-di-p-ethylphenyl guanidine (p-ethylDPhG) (174):
1
 Following the general 
procedure the product was obtained by silica gel chromatography  (hexanes: EtOAc: NEt3 = 
1:4:0.050, Rf = 0.18) to give N,N’-di-p-ethylphenyl guanidine as a white solid, 70.6 mg, 41 % 
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yield. Mp: 94.6 -96.5 °C. 
1
H NMR (250 MHz, CDCl3): δ 1. 13 (t, J = 7.48, J = 7.34, 6H), 2.53 (q, J 
= 14.9 Hz, 4H), 4.19 (s, 3H), 6.89 (dd J = 7.8Hz, J = 7.1 Hz, 2H), 6.94 (dd, J = 8.1, J = 15.8Hz, 
5H). 
13
C NMR (100 MHz, CDCl3): δ 141.98, 141.03, 137.82, 128.75, 128.56, 126.80, 123.00, 
122.32, 28.33, 28.26, 15.80, 15.72, 15.44. MS (ESI): C19H17N3 Calcd. for ([M+H]
+
) 268.1, found 
268.1. 
 
N,N’-di-p-t-butylphenyl guanidine (p-t-ButylDPhG) (175): Following the general 
procedure the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt3 = 
1:4:0.025, Rf = 0.14) to give N,N’-di-p-t-butylphenyl guanidine as a white solid, 61 mg, 39 % yield. 
Mp: 164.9 -166.0 
°
C. 
1
H NMR (250 MHz, CDCl3): δ 1.23 (s, 18H), 4.56 (s, 3H), 6.97 (d, J = 7.19, 
4H), 7.24(d, J = 7.37 Hz, 4H). 
13
C NMR (100 MHz, CDCl3): δ 149.59, 146.32, 141.02, 126.31, 
122.77, 34.30, 31.44. MS (ESI): C21H29N3 Calcd. for ([M+H]
+
) 324.2, found 324.2. 
 
N,N’-diphenyl guanidine (DPhG) (176):
1
 Following the general procedure the product 
was obtained by silica gel chromatography (hexanes: EtOAc: NEt3 = 1:4:0.025 to 1:4:0.075, Rf = 
0.22) to give N,N’-diphenyl guanidine as a white solid, 94.5 mg, 83 % yield. Mp: 141.0 - 143.0
 °
C.
 
1
H NMR (250 MHz, CDCl3): δ 4.69 (br, s, 2H), 6.84-6.96 (m, 6H), 7.12 (t, J = 8 Hz, 4H).
 13
C NMR 
(62.5 MHz, CDCl3): δ 149.61, 143.99, 129.43, 123.25, 122.989. MS (ESI) Calcd. for C13H13N3 
([M+H]
 +
) 212.1, found 212.1. 
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N,N’-di-naphthalen-2-yl-guanidine (2-NaphG) (177):
1
 Following the general procedure 
the product was obtained by silica gel chromatography  (hexanes: EtOAc: NEt3 = 1:4:0.025, Rf  = 
0.25) to give N,N’-di-naphthalen-2-yl-guanidine as a white solid, 40.2 mg, 66 % yield.
 
Mp: 193.5 - 
194.5 
°
C. 
13
C NMR (63 MHz, DMSO-d6) δ 148.59, 134.16, 128.82, 128.18, 127.37, 126.67, 
125.88, 123.30. MS (ESI): C21H17N3 Calcd. for ([M+H]
+
) 312.1, found 312.1 
 
N,N’-di-naphthalen-1-yl-guanidine (1-NaphG) (178):
1
 Following the general procedure 
the product was obtained by silica gel chromatography  (hexanes: EtOAc: NEt3 = 1:4:0.025, Rf = 
0.15) to give N,N’-di-naphthalen-1-yl-guanidine as a white solid, 40.2 mg, 50% yield. Mp: 200.2 - 
201.3 °C. 
1
H NMR (250 MHz, DMSO-d6): δ 5.45 (s, 2H), 7.50-7.40 (m, 8H), 7.86 (d, J = 6.83 Hz, 
3H), 8.17-8.09 (m, 3H). 
13
C NMR (100 MHz, Acetone-d6): δ 134.88, 128.22, 126.32, 125.84, 
125.16, 123.33, 122.29, 118.33. MS (ESI): C21H17N3 Calcd. for ([M+H]
+
) 312.1, found 312.1. 
 
 
N,N’-di-(2,4-dimethyl-phenyl) guanidine (2, 4-CH3DPhG) (179):  Following the general 
procedure the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 
1:4:0.025 to 1:4:0.050, Rf = 0.13) to give N,N’-di-(2,4-dimethyl-phenyl) guanidine as a white solid, 
104.9 mg, 80 % yield. Mp: 159.3 - 161.0 °C. 
1
H NMR (250 MHz, CDCl3): δ 2.15 (s, 3H), 2.21 (s, 
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3H), 6.90 (d, J = 2.45 Hz, 4H), 6.94 (s, 2H). 
13
C NMR (100 MHz, CDCl3): δ 149.59, 131.76, 
127.62, 124.94, 21.03, 18.08. MS (ESI): C17H21N3 Calcd. for ([M+H]
+
) 268.2, found 268.2. 
 
N, N’-di-o-anisole guanidine (o-MeODPhG) (180):
1 
Following the general procedure the 
product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:1:0.075, Rf = 0.26) 
to give N, N’-di-o-anisole guanidine as a yellow solid, 31.5 mg, 47 % yield. Mp: 112.0 - 113.0
 °
C. 
1
H NMR (250 MHz, CDCl3): δ 3.75 (s, 6H) 6.85-6.80 (m, 6H), 7.33-7.30 (d, 2H). 
13
C NMR (62.5 
MHz, CDCl3): δ 150.82, 148.87, 123.11, 122.42, 121.18, 111.20, 55.71. MS (ESI): C15H17N3O2 
Calcd. for ([M+H]
+
) 272.1, found 272.1. 
 
N,N’-di-m-anisole guanidine (m-MeODPhG) (181): The product was obtained by flash 
chromatography (hexanes:EtOAc:NEt3 = 1:4:0.50 to 1:4:0.75, Rf  = 0.31) to give N,N’-di-m-anisole 
guanidine as a light yellow solid, 13.8 mg, 20 % yield. Mp:116.0 – 118.0 
°
C. 
1
H NMR (250 MHz, 
CDCl3): δ 4.80 (s, 3H), 6.95 (d, J = 8.5Hz, 4H), 7.30 (d, J = 8.5Hz, 4H). 
13
C NMR (62.5 MHz, 
CDCl3): δ 149.38, 142.87, 138.37, 132.42, 124.80, 124.50, 116.14. MS(ESI): C15H17N3 O2 Calcd. 
for ([M+H]
+
) 272.1, found 272.1. 
 
N,N’-di-o-fluorophenyl guanidine (o-FDPhG) (182): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 10:1, R f = 0.36) to give 
N,N’-di-o-fluorophenyl guanidine as a white solid, 78.4 mg, 62 % yield. Mp: 92.2 - 93.5 
°
C. 
1
H 
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NMR (400 MHz, CDCl3): δ 4.90 (s, 3H), 7.09-7.02 (d, J = 8.5Hz, 4H), 7.46 (t, J = 8.0Hz, 2H). 
13
C 
NMR (100 MHz, CDCl3): δ 156.10, 155.12, 1495.67, 131.96, 126.25, 123.83, 111.11 MS (ESI): 
C13H11N3 F2 Calcd. for ([M+H]
+
) 248.1, found 248.1. 
 
N,N’-di-m-fluorophenyl guanidine (m-FDPhG) (183): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 8:1, R f = 0.44) to give 
N,N’-di-m-fluorophenyl guanidine as a white solid, 66.7 mg, 53 % yield. Mp: 117.6 - 118.2 °C. 
1
H 
NMR (250 MHz, CDCl3): δ 4.90 (s, 3H), 6.72 (t, J = 8.5Hz, 2H), 6.88-6.76 (m, 4H), 7.20 (d, J = 
8.5Hz, 2H). 
13
C NMR (100 MHz, CDCl3): δ 165.42, 161.51, 149.10, 145.62, 145.47, 130.61, 
130.45, 118.06, 118.02, 110.20, 109.86, 109.83, 109.46. MS (ESI): C13H11N3 F2 Calcd. for 
([M+H]
+
) 248.1, found 248.1. 
 
N,N’-di-p-fluorophenyl guanidine (p-FDPhG) (184): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:4:0.025 to 
4:1:0.075, Rf = 0.56) to give N,N’-di-p-fluorophenyl guanidine as a light pink solid, 34.6 mg, 19 % 
yield. Mp: 130.4-131.4°C. 
1
H NMR (250 MHz, CDCl3): δ 5.14 (s, 3H), 7.01(m, 8H). 
13
C NMR (100 
MHz, CDCl3): δ 160.67, 158.26, 150.49, 139.90, 124.95, 124.88, 116.36, 116.14. MS(ESI): 
C13H11N3 F2 Calcd. for ([M+H]
+
) 248.1, found 248.1. 
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N,N’-di-p-chlorophenyl guanidine (p-ClDPhG) (185): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:4:0.075, Rf = 
0.20), to give N,N’-di-p-chlorophenyl guanidine as a white solid, 50.1 mg, 35 % yield. Mp: 139.5 -
140.5 °C. 
1
H NMR (250 MHz, CDCl3): δ 4.85 (s, 3H), 6.94 (d, J = 8.7Hz, 4H), 7.17 (d, J = 8.8Hz, 
4H). 
13
C NMR (62.5 MHz, CDCl3): δ 149.46, 142.31, 129.48, 128.57, 124.12. MS(ESI): C13H11N3 
Cl2 Calcd. for ([M+H]
+
) 281.1, found 281.1. 
 
N,N’-di-p-bromophenyl guanidine (p-BrDPhG) (186): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:4:0.25 to 
1:4:0.075, Rf  = 0.56) to give N,N’-di-p-bromophenyl guanidine as a light pink solid, 34.6 mg, 19 % 
yield. Mp: 169 - 170 
°
C. 
1
H NMR (250 MHz, CDCl3): δ 4.79 (br, s, 3H), 6.89 (d, J = 8.5Hz, 4H), 
7.32 (d, J = 8.5Hz, 4H). 
13
C NMR (62.5 MHz, CDCl3): δ 149.38, 142.87, 138.37, 132.42, 124.84, 
124.50, 116.14. MS(ESI): C13H11N3 Br2 Calcd. for ([M+H]
+
) 369.9, found 369.9. 
 
N,N’-di-m-trifluoromethanephenyl guanidine (m-CF3DPhG) (187): The product was 
obtained by flash chromatography (hexanes:EtOAc:NEt3 = 1:4:0.075, Rf  = 0.50) to give N,N’-di-m-
trifluoromethanephenyl guanidine as a white solid, 26.1 mg, 15 % yield. Mp: 86.2 - 88.2 
°
C. 
1
H 
NMR (250 MHz, CDCl3): δ 6.88(m, 6H), 7.19 (s, 2H), 7.32 (s, 2H). 
13
C NMR (62.5 MHz, CDCl3): δ 
150.83, 148.88, 123.12, 122.43, 121.19, 55.73. MS(ESI): C15H11N3 F6 calcd. for ([M+H]
+
) 348.1, 
found 348.1. 
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N,N’-di-p-cyanophenyl guanidine (p-CNDPhG) (188): The product was obtained by 
flash chromatography (hexanes:EtOAc = 8:1, Rf = 0.30), to give N,N’-di-p-cyanophenyl guanidine 
as a white solid, 19.7 mg, 15 % yield. 
1
H NMR (250 MHz, DMSO-d6) δ 8.89 (s, 1H), 7.71 (s, 8H), 
5.75 (s, 2H). 
13
C NMR (63 MHz, DMSO-d6) δ 148.42, 133.08, 119.98, 102.31.MS (ESI): C15H11N5 
Calcd. for ([M+H]
+
) 262.1, found 262.1. 
 
N,N’-di-p-nitrophenyl guanidine (p-NO2DPhG) (189): Following the general procedure 
the product was obtained by silica gel chromatography (hexanes: EtOAc: NEt 3 = 1:4:0.025, Rf  = 
0.72) to give N,N’-di-p-nitrophenyl guanidine as an orange solid, 35.0 mg, 46 % yield. Mp: 141.2 - 
142.2 
°
C. 
1
H NMR (250 MHz, CDCl3): δ 4.38 (s, 3H), 6.62 (d, J = 9.11 Hz, 4H), 8.07 (d, J = 9.06 
Hz, 4H). 
13
C NMR (62.5 MHz, CDCl3): δ 151.29, 126.38, 125.22, 113.39, 112.23. MS (ESI): 
C13H11N5O4 Calcd. for ([M+H]
+
) , not found. 
 
N,N’-di-m-chlorophenyl guanidine (m-ClDPhG) (190): The product was obtained by 
flash chromatography (hexanes:EtOAc:NEt3 = 1:4:0.75, Rf = 0.22) to give N,N’-di-m-chlorophenyl 
guanidine as a white solid, 34.5 mg, 24% yield. M.p.142 - 143 
°
C. 
1
H NMR (250 MHz, CDCl3): δ 
4.85 (s, 3H), 6.95 (d,d, J = 8.3Hz, J = 13.3Hz, 4H), 7.04 (s, 2H), 7.12 (d, J = 7.86Hz, 2H), 7.18(d, 
J = 4.43Hz, 2H). 
13
C NMR (250 MHz, CDCl3): δ 148.78, 145.11, 134.91, 130.43, 123.38, 122.71, 
120.77. MS (ESI): C13H11N3 Cl2 Calcd. for ([M+H]
+
) 281.1, found 281.1. 
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N,N’-di-m-bromophenyl guanidine (m-BrPhG) (191): The product was obtained by 
flash chromatography (hexanes:EtOAc:NEt3 = 1:4:0.25, Rf = 0.40) to give N,N’-di-m-bromophenyl 
guanidine as a light pink solid, 38 mg, 20 % yield. 
1
H NMR (250 MHz, CDCl3): δ 7.20 (s), 7.09 (d, 
J = 5.4 Hz), 6.95 (d, J = 3.8 Hz), 4.87 (s). 
13
C NMR (62.5 MHz, CDCl3):  δ 149.12, 130.63, 
126.20, 125.57, 122.64, 121.33.  MS(ESI): C13H11N3 Br2 Calcd. for ([M+H]
+
) 369.9, found 369.9. 
 
N,N’-di-m-cyanophenyl guanidine (m-CNDPhG) (192): The product was obtained by 
flash chromatography (hexanes:EtOAc = 8:1, Rf  = 0.26) N,N’-di-m-cyanophenyl guanidine as a 
white solid, 14.8 mg, 11 % yield.. 
1
H NMR (250 MHz, DMSO-d6) δ 8.72 (s, 1H), 7.72 – 7.07 (m, 
8H), 5.61 (s, 2H).
 
 
13
C NMR (63 MHz, DMSO-d6) δ 148.81, 129.96, 124.38, 119.10, 111.47, 
106.24, 98.65. MS(ESI): C15H11N5  Calcd. for ([M+H]
+
) 262.1, found 262.1. 
 
N,N’-di-Thiophen-3-yl-guanidine (3-ThG) (193): Following the general procedure the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.25) to give 
N,N’-di-Thiophen-3-yl-guanidine as a peach color solid, 25.0 mg, 75 % yield. Mp: 128.0 - 129.4 
°C. 
1
H NMR (250 MHz, CDCl3): δ 3.59 (s, 5H), 6.83 (s, 2H), 7.20(s, 2H). 
13
C NMR (62.5 MHz, 
CDCl3): δ 151.59, 140.41, 125.93, 124.63, 112.85. MS(ESI): C9H9N3S2 calcd. for ([M+H]
+
) 224.0, 
found 224.0. 
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N,N’-di-(4-bromo-3-fluoro-phenyl) guanidine (p-Br-m-FDPhG) (194): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 8:1, 
Rf  = 0.92) to give N,N’-di-(4-bromo-3-fluoro-phenyl) guanidine as a white solid, 111.1 mg, 55 % 
yield. Mp: 139.2-141.1 °C. 
1
H NMR (250 MHz, CDCl3): δ 6.99 (dd, J = 8.41, 1.90, 2H), 7.15 (dd, J 
= 8.5Hz, J = 2.72Hz, 2H), 7.30 (t, J =7.98Hz, J = 7.16Hz, 2H). 
13
C NMR (62.5 MHz, CDCl3): δ 
163.20, 160.71, 140.36, 129.38, 128.09, 122.98, 122.90, 119.79, 119.52. MS (ESI): C13H11N3 
Br2F2 Calcd. for ([M+H]
+
) 405.9, found 405.9. 
 
N,N’-di-(4-chloro-3-methyl-phenyl) guanidine (p-Cl-m-CH3DPhG) (195): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4,  
Rf  = 0.28) to give  N,N’-di-(4-chloro-3-methyl-phenyl) guanidine as a white solid, 106.7 mg, 67 % 
yield. Mp: 117.8-173.2 °C. 
1
H NMR (250 MHz, CDCl3): δ 2.23 (s, 6H), 4.62 (s, 3H), 6.82 (t, J = 
8.28 Hz, J = 9.38 Hz, 4H), 7.17 (d, J = 6.83 Hz, 2H). 
13
C NMR (100 MHz, CDCl3): δ 149.69, 
142.52, 137.29, 129.98, 129.03, 125.62, 121.78, 20.32. MS (ESI): C15H13N3Cl2 calcd. for ([M+H]
+
) 
308.0, found 308.0. 
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N,N’-di-m-methylphenyl-N’-methyl-guanidine (N’-Me-m-MeDPhG) (198): Following 
the general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 
1:4, Rf  = 0.25) to give N,N’-di-m-methylphenyl-N’-methyl-guanidine as a brown color oil, 64.7mg, 
25 % yield. 
1
H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 6.4 Hz, 4H), 6.96 (s, 4H), 5.42 (s, 2H), 2.58 
(d, J = 7.1 Hz, 5H), 1.18 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 142.02, 139.29, 129.16, 124.90, 
124.02, 120.31, 29.90, 21.54. MS(ESI): C14H13N3 calcd. for ([M+H]
+
) 282.2, found 282.2. 
 
N,N’-di-m-chloropheyl-N’-methyl-guanidine (N’-Me-m-ClDPhG) (199): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, 
Rf  = 0.29) to give N,N’-di-m-chlorophenyl-N’-methyl-guanidine as a brown color oil, 69.1.5 mg, 30 
% yield. 
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.17 (m, 3H), 7.09 – 6.99 (m, 3H), 6.97 – 6.88 (m, 
2H), 4.12 (s, 2H), 2.92 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 148.48, 134.88, 130.57, 130.36, 
127.05, 126.61, 124.93, 123.22, 122.86, 122.07, 121.38, 120.93, 28.67. MS(ESI): C14H13Cl2N3 
calcd. for ([M+H]
+
) 254.1, found 254.1. 
 
N,N’-di-p-ethylphenyl-N’-methyl-guanidine (N’-Me-p-EtDPhG) (200): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, 
Rf  = 0.25), to give N,N’-di-p-ethylphenyl-N’-methyl-guanidine as a brown color oil, 47.3mg, 17 % 
yield. 
1
H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 6.4 Hz, 4H), 6.96 (s, 4H), 5.42 (s, 2H), 2.58 (d, J = 
7.1 Hz, 5H), 1.18 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 140.13, 128.79, 123.67, 28.35, 28.19, 
15.60. MS(ESI): C14H13N3 calcd. for ([M+H]
+
) 282.2, found 282.2. 
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N,N’-di-p-fluoropheyl-N’-methyl-guanidine (N’-Me-p-FDPhG) (201): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, 
Rf = 0.26), to give N,N’-di-p-fluoropheyl-N’-methyl-guanidine as a brown color oil, 78.5 mg, 31 % 
yield. 
1
H NMR (400 MHz, CDCl3): δ 2.85 (s, 3H), 4.35 (s, 2H), 6.97(s, 8H). 
13
C NMR (100 MHz, 
CDCl3): δ 158.72, 125.31, 115.86, 90.80, 29.11. MS(ESI): C14H13N3 calcd. for ([M+H]
+
) 262.0, 
found 262.0. 
 
N,N’-di-p-trifluoromethylphenyl-N’-methyl-guanidine (N’-Me-p-CF3DPhG)(202): 
Following the general procedure the product was obtained by silica gel chromatography 
(hexanes: EtOAc = 1:4, Rf  = 0.70) to give N,N’-di-p-trifluorophenyl-N’-methyl-guanidine as a 
brown color oil, 142.6 mg, 40 % yield. 
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.17 (m, 3H), 7.09 – 
6.99 (m, 3H), 6.97 – 6.88 (m, 2H), 4.12 (s, 2H), 2.92 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
148.07, 126.64, 126.60, 121.85, 38.57, 28.83. MS(ESI): C14H13Cl2N3 calcd. for ([M+H]
+
) 362.1, 
found 362.1. 
 
N,N’-di-naphth-1-yl-N’-methyl-guanidine (N’-Me-p-FDPhG) (203): Following the 
general procedure the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, 
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Rf  = 0.30), to give N,N’-di-naphth-1-yl-N’-methyl-guanidine as a brown color oil, 67.1 mg, 21 % 
yield. 
13
C NMR (101 MHz, DMSO-d6) δ 134.37, 133.47, 130.80, 129.46, 128.84, 128.36, 128.22, 
127.77, 127.43, 126.71, 126.37, 125.31, 124.20, 122.30, 118.89, 118.07, 79.62.  MS(ESI): 
C22H19N3 Calcd. for ([M+H]
+
) 325.1, found 325.1. 
 
6.3 Experimental Procedure Chapter 4, Section 4.2 
General procedure for preparation of N’-o-tolyl benzamidine (o-TB):  
To a screw-cap reaction tube was added benzamidine hydrochloride (1 mmol, 0.1556 g), 
2-iodotoluene (1 mmol, 0.13 mL), CuI (0.1 mmol, 0.190 g), and Cs2CO3 (0.6499 g, 2 equiv.). The 
reaction tube was placed under high vacuum, backfilled with argon and repeated three times. 
Dimethylformamide (2 mL) was added using a syringe and the mixture was heated to the desired 
temperature with use of an oil bath. After the resulting solution was stirred for 24 hours, the 
product was extracted using ethyl acetate, washed with water 3 times, and the organic layer was 
dried over anhydrous Na2SO4. Following concentration under reduced pressure, the residue was 
purified by silica gel chromatography (4:1 = EtOAc:hexanes) to afford the desired product.  
 
N’-o-tolyl benzamidine  (o-TB) (207):  Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 0.60) to give N’-o-tolyl 
benzamidine as a white solid, 190.1 mg, 89 % yield with spectral properties reported in the 
literature.
88, 89
  Mp: 106.3 -107.0
 °
C. 
1
H NMR (250 MHz, DMSO-d6): δ 2.12 (s, 3H), 6.12 (br, s, 
2H), 6.78 (d, 1H, J = 7.55 Hz), 6.94 (t, 1H, J = 7.27 Hz), 7.15-7.24 (m, 2H), 7.50 (d, 3H, J = 11.08 
Hz), 8.03 (d, 2H, J = 6.15 Hz). 
13
C NMR (62.5 MHz, DMSO-d6): δ 152.9, 149.1, 135.8, 130.3, 
129.9, 128.7, 127.1, 126.6, 125.9, 121.8, 120.9, 17.6. HRMS (ESI): C14H14N2 Calcd. for ([M+H]
+
) 
211.1229, found 211.1253.  
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N’-m-tolyl benzamidine  (m-TB) (209):  Following the general procedure, the product 
was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.38) to give N’-m-tolyl 
benzamidine as a light yellow solid, 115.4 mg, 72% yield with spectral properties reported in the 
literature.
166
 Mp: 106.5-107.4
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H), 4.97 (br, s, 2H), 6.78 
(t, 2H, J = 8.04 Hz), 6.87 (d, 1H, J = 7.48 Hz), 7.32 (t, 1H, J = 7.11 Hz), 7.35-7.46 (m, 3H), 7.83 
(d, 2H, J = 7.39 Hz). 
13
C NMR (100 MHz, CDCl3): δ 155.1, 149.7, 139.4, 136.1, 130.7, 129.5, 
128.7, 127.0, 126.8, 124.0, 122.5, 118.8, 21.7. HRMS (ESI): C14H14N2 Calcd. for ([M+H]
+
) 
211.1229, found 211.1253.  
 
N’-p-tolyl benzamidine (p-TB) (210): Following the general procedure 1, the product 
was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 0.35) to give N’-p-tolyl 
benzamidine as a white solid, 141.9 mg, 66 % yield with spectral properties reported in the 
literature.
89
 Mp: 93.1 - 94.3
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H), 4.87 (br, s, 2H), 6.88 
(d, 2H, J = 7.78 Hz), 7.14 (d, 2H, J = 7.53 Hz), 7.39-7.45 (m, 3H), 7.83 (d, 2H, J = 6.22 Hz) 
13
C 
NMR (100 MHz, CDCl3): δ 155.3, 147.1, 136.1, 132.5, 130.6, 130.2, 128.7, 126.9, 126.8, 121.7, 
21.1. HRMS (ESI): C14H14N2 Calcd. for ([M+H]
+
) 211.1229, found 211.1262. 
 
N’-2,4-dimethylphenyl benzamidine  (2,4-DMePhB) (211): Following the general 
procedure 1, the product was obtained by silica gel chromatography (hexanes:EtOAc:= 1:4, R f = 
0.81) to give N’-2,4-dimethyl-phenyl benzamidine as a white solid, 110.3 mg, 50 % yield. Mp: 
104.5 - 105.5
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 2.15 (s, 3H), 2.29 (s, 3H), 4.73 (br, s, 2H), 6.76 (d, 
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1H, J = 7.66 Hz), 6.97 (d, 1H, J = 7.62 Hz), 7.03 (s, 1H), 7.42-7.45 (m, 3H), 7.83 (d, 2H, J = 6.63 
Hz). 
13
C NMR (100 MHz, CDCl3): δ 154.4, 145.5, 136.1, 132.5, 131.7, 130.6, 129.5, 128.9, 128.7, 
127.6, 127.2, 126.9, 121.2, 21.0, 17.8. HRMS (ESI): C15H16N2 Calcd. for ([M+H]
+
) 225.1386, 
found 225.1383. 
 
N’-o-methoxy-phenyl benzamidine (o-OMePhB) (212):  Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 
0.74) to give N’-o-methoxy-phenyl benzamidine as a brown solid, 114.5 mg, 55 % yield with 
spectral properties reported in the literature.
88
 Mp: 110.2 - 111.0
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 
3.79 (s, 3H), 5.09 (br, s, 1H), 6.91-6.96 (m, 2H), 7.02 (t, 1H, J = 7.26 Hz), 7.14 (s, 1H), 7.42 (s, 
3H), 7.84 (s, 2H) 
13
C NMR (100 MHz, CDCl3): δ 150.9, 137.3, 136.4, 130.7, 128.7, 127.1, 123.9, 
122.7, 121.6, 112.1, 56.1. HRMS (ESI): C14H14ON2 Calcd. for ([M+H]
+
) 227.1179, found 227.1187. 
 
 
N’-m-methoxy-phenyl benzamidine (m-OMePhB)(213):  Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc  = 1:4, Rf = 
0.74) to give N’-m-methoxy-phenyl benzamidine as a cream solid, 70.3 mg, 31 % yield with 
spectral properties reported in the literature.
88
 Mp: 110.2 - 111.0
 °
C. 
1
H NMR (400 MHz, CDCl3) δ 
7.83 (d, J = 5.8 Hz, 2H), 7.51 – 7.36 (m, 3H), 7.23 (s, 1H), 6.58 (dd, J = 19.2, 9.0 Hz, 3H), 3.77 (s, 
3H).
 13
C NMR (101 MHz, CDCl3) δ 160.76, 154.71, 151.09, 135.72, 130.54, 130.22, 128.48, 
126.77, 113.80, 108.93, 107.09, 77.36, 77.04, 76.72, 55.18. C14H14ON2 Calcd. for ([M+H]
+
) 227.1, 
found 227.1. 
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N’-p-methoxy-phenyl benzamidine (p-OMePhB)(214): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f  = 
0.74) to give N’-p-methoxy-phenyl benzamidine as a cream solid, 86.0 mg, 38 % yield with 
spectral properties reported in the literature.
88 
Mp: 110.2 – 111.8 °C. 
1
H NMR (400 MHz, CDCl3) δ 
7.83 (s, 4H), 7.42 (d, J = 6.8 Hz, 6H), 6.90 (s, 8H), 4.84 (s, 3H), 3.78 (s, 6H).
 13
C NMR (101 MHz, 
CDCl3) δ 155.57, 130.43, 128.47, 126.71, 122.50, 114.81, 77.32, 77.00, 76.68, 55.45.  C14H14ON2 
Calcd. for ([M+H]
+
) 227.1179, found 227.1187. 
 
N’-(p-(benzyloxy)phenyl)benzamidine  (p-BnOPhB)(215): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 
0.83) to give  N’-(p-(benzyloxy)phenyl)benzamidine as a white solid, 113.5 mg, 46 % yield. M.p. 
163.2 - 164.2. 
1
H NMR (400 MHz, CDCl3) δ 7.84 (s, 7H), 7.51 – 7.27 (m, 28H), 7.03 – 6.80 (m, 
15H), 5.04 (s, 8H), 4.86 (s, 5H), 1.58 (s, 3H).
 13
C NMR (101 MHz, CDCl3) δ 130.45, 128.50, 
127.85, 127.47, 126.84, 122.77, 122.52, 115.92, 77.28, 76.96, 76.64, 70.36. C20H18N2O Calcd. 
for ([M+H]
+
) 281.0, found 281.0. 
 
N’-p-tert-butylphenyl benzamidine  (p-tBuPhB)(216):  Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.83) to give 
N’-p-tert-butylphenyl benzamidine as a white solid, 113.5 mg, 46 % yield. M.p. 163.2-164.2 °C. 
1
H 
NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.1 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H), 
6.92 (d, J = 8.4 Hz, 1H), 4.86 (s, 1H), 1.31 (s, 5H). MS (ESI): C17H20N2 Calcd. for ([M+H]
+
) 253.0, 
found 253.0. 
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N’-phenyl benzamidine (PhB)(217):  Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 0.41) to give N’-phenyl 
benzamidine as a white solid, 129.8 mg, 84 % yield with spectral properties reported in the 
literature.
89
  Mp: 110.0-111.2
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 4.83 (br, s, 1H), 6.97 (d, 2H, J = 
5.88 Hz), 7.06 (t, 1H, J = 6.68 Hz), 7.34 (s, 2H), 7.43 (d, 4H), 7.86 (br, s, 2H). 
13
C NMR (100 
MHz, CDCl3): δ 130.81, 129.7, 128.8, 127.6, 127.0, 123.3, 121.9. HRMS (ESI): C13H12N2 Calcd. 
for ([M+H]
+
) 197.1073, found 197.1075. 
 
N’-naphthalen-1-yl benzamidine (1-naphthaB) (218): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.73) to give 
N’-naphthalen-1-yl benzamidine as a cream color solid, 129.1 mg, 51 % yield. Mp: 137.6 - 138.2
 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 4.71 (br, s, 2H), 6.96 (d, 1H, J =7.02 Hz), 7.31-7.52 (m, 7H), 
7.76 (d, 1H, J = 7.47 Hz), 7.93 (d, 3H, J = 7.20 Hz). 
13
C NMR (100 MHz, CDCl3): δ 154.9, 146.4, 
135.8, 134.9, 130.9, 128.8, 128.6, 128.5, 128.2, 127.3, 127.1, 126.8, 126.7, 126.5, 126.3, 125.5, 
124.0, 123.2, 116.7, 116.5. HRMS (ESI): C17H14N2 Calcd. for ([M+H]
+
) 247.1230, found 247.1232. 
 
Nʹ-naphthalen-2-yl benzamidine (2-naphthaB) (219): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.71), to give 
Nʹ-naphthalen-2-yl benzamidine as a cream color solid, 163.3 mg, 66 % yield. Mp: 136.6 - 137.4
 
°
C. 
1
H NMR (100 MHz, DMSO-d6): δ 4.89 (br, s, 2H), 7.11 (d, 1H, J = 7.02 Hz), 7.11-7.40 (m, 5H), 
7.75-7.82 (m, 5H). 
13
C NMR (62.5 MHz, CDCl3): δ 154.1, 148.6, 135.9, 134.4, 130.1, 129.5, 
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128.8, 128.0, 127.5, 127.1, 126.9, 126.7, 125.8, 123.6, 123.4, 117.0. HRMS (ESI): C17H14N2 
Calcd. for ([M+H]
+
) 247.12297, found 247.12343. 
 
N’-pyrid-2-yl benzamidine (2-pyridylB) (220): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.73) to give N’-
pyrid-2-yl benzamidine as a white color solid, 161.1 mg, 79 % yield. Mp: 137.6 - 138.2
 °
C. 1H 
NMR (250 MHz, DMSO-d6) δ 9.80 (s, 1H), 8.38 (s, 1H), 8.10 (d, J = 5.5 Hz, 1H), 7.74 (d, J = 7.4 
Hz, 1H), 7.54 (s, 2H), 7.36 (s, 2H), 7.16 (d, J = 7.9 Hz, 1H), 7.04 (d, J = 5.6 Hz, 1H), 6.87 – 6.34 
(m, 1H). 
13
C NMR (63 MHz, DMSO-d6) δ 162.84, 157.88, 147.91, 146.12, 137.57, 136.43, 
130.43, 128.73, 128.10, 127.95, 127.20, 121.77, 118.49, 117.31. MS (ESI): C17H14N2 Calcd. for 
([M+H]
+
) 198.0, found 198.0.  
 
N’-thiophen-2-yl benzamidine (2-ThioB)(221): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 0.85), to give N’-
thiophen-2-yl benzamidine as a light cream solid, 42.2 mg, 21 % yield. Mp: 115.1-116.9 
°
C. 
1
H 
NMR (250 MHz, CDCl3) δ 7.76 (d, J = 6.5 Hz, 2H), 7.37 (q, J = 5.5 Hz, 3H), 7.25 (dd, J = 4.9, 3.1 
Hz, 1H), 6.81 (d, J = 4.5 Hz, 1H), 6.65 (d, J = 1.7 Hz, 1H), 4.74 (s, 2H). 
13
C NMR (101 MHz, 
CDCl3) δ 130.58, 128.52, 126.69, 125.59, 124.17, 109.65. M.S.(ESI) C11H10N2S Calcd. for 
([M+H]
+
) 203.0, found 203.0. 
 
N’-o-fluoro-phenyl benzamidine  (o-FPhB)(222):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.81) to give N’-o-
fluoro-phenyl benzamidine as a white solid, 89.5 mg, 42 % yield. Mp: 80.7 - 82.1
°
C. 
1
H NMR (400 
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MHz, CDCl3) δ 7.81 (s, 2H), 7.55 – 7.29 (m, 3H), 7.05 (d, J = 29.5 Hz, 3H), 6.90 (s, 1H), 5.11 (s, 
2H). 
13
C NMR (101 MHz, CDCl3) δ 155.26 (s), 130.74 (s), 128.53 (d, J = 4.1 Hz), 126.88 (d, J = 
10.7 Hz), 126.49 (s), 124.74 (d, J = 3.5 Hz), 124.33 (s), 124.08 (d, J = 7.2 Hz), 122.95 (s), 116.19 
(dd, J = 21.1, 11.7 Hz).MS (ESI) C13H11N2F1 Calcd. for ([M+H]
+
) 215.0, found 215.0. 
 
N’-m-fluoro-phenyl benzamidine  (m-FPhB)(223):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.59) to give N’-
m-fluoro-phenyl benzamidine as a white solid, 204.2 mg, 95 % yield with spectral properties 
reported in the literature.
5  
Mp: 85.3-86.2 °C. 
1
H NMR (400 MHz, CDCl3) δ 7.81 (s, 2H), 7.43 (dd, 
J = 14.6, 6.7 Hz, 3H), 7.27 (d, J = 6.2 Hz, 1H), 6.70 (dd, J = 18.5, 8.9 Hz, 3H), 4.91 (s, 2H).
 13
C 
NMR (101 MHz, CDCl3) δ 164.95, 162.66, 151.77, 135.42, 130.71, 130.58, 128.53, 126.77, 
126.49, 117.37, 109.79, 109.58, 108.95, 108.73, 77.36, 77.04, 76.72.  MS (ESI): C13H11N2F1 
Calcd. for ([M+H]
+
) 215.0, found 215.0. 
 
Nʹ-p-fluoro-phenyl benzamidine  (p-FPhB)(224):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.61) to give Nʹ-p-
fluoro-phenyl benzamidine as a white solid, 108.3 mg, 49 % yield with spectral properties 
reported in the literature.
5
 Mp: 120.7 - 121.5
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 4.82 (br, s, 2H), 
6.91 (dd, 2H, J = 4.93 Hz, J = 8.22 Hz,), 7.03 (dd, 2H, J = 8.13 Hz, J = 7.90 Hz), 7.41-7.46 (m, 
3H), 7.85 (d, 2H, J = 5.71 Hz).
13
C NMR (100 MHz, CDCl3): δ 160.4, 158.1 (d, J = 240.4 Hz), 
155.3, 145.9, 135.8, 130.8, 128.7, 127.1 (d, J = 19.6 Hz) 126.9, 122.9, 122.9, 116.4(d, J = 22 Hz), 
116.2 HRMS (ESI): C13H11N2F1 Calcd. for ([M+H]
+
) 215.0979, found 215.0979. 
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N’-p-chloro-phenyl benzamidine (p-ClPhB) (225): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f  = 0.62) to give N’-p-
chloro-phenyl benzamidine as a white solid, 123.5 mg, 53% yield with spectral properties 
reported in the literature.
89
 Mp: 113.9 - 114.9
 °
C. 
1
H NMR (250 MHz, DMSO-d6): δ 6.48 (s, 2H), 
6.88 (d, 2H, J = 7.80 Hz), 7.32 (d, 2H, J = 8.01 Hz), 7.42-7.54 (m, 3H), 7.97 (s, 2H). 
13
C NMR 
(62.5 MHz, DMSO-d6): δ 154.4, 149.7, 135.7, 130.1, 128.9, 128.9, 127.9, 127.1, 126.0, 125.5, 
124.8, 123.6, 123.5. HRMS (ESI): C13H11ClN2 Calcd. for ([M+H]
+
) 231.0686, found 231.0686. 
 
N’-o-chloro-phenyl benzamidine (p-ClPhB)(226): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.86) to give Nʹ-o-
chloro-phenyl benzamidine as a white solid, 143.2 mg, 53 % yield Mp: 111.1 - 113.0
 °
C. 
1
H NMR 
(400 MHz, CDCl3) δ 7.84 (d, J = 6.0 Hz, 3H), 7.52 – 7.35 (m, 6H), 7.21 (dd, J = 14.7, 7.4 Hz, 2H), 
6.99 (t, J = 7.1 Hz, 3H), 4.98 (s, 3H).
 13
C NMR (101 MHz, CDCl3) δ 130.91, 130.16, 128.56, 
127.72, 127.03, 124.27, 123.50, 77.31, 76.99, 76.68, 42.60.  MS (ESI): C13H11N3 Calcd. for 
([M+H]
+
) 231.0, found 231.0. 
 
Nʹ-m-chloro-phenyl benzamidine (p-ClPhB) (227): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f  = 0.83) to give 
Nʹ-m-chloro-phenyl benzamidine as a white solid, 106.6 mg, 48 % yield. Mp: 112.9 - 113.9
 °
C. 
1
H 
NMR (250 MHz, CDCl3) δ 7.74 (d, J = 6.5 Hz, 2H), 7.36 (q, J = 6.6 Hz, 3H), 7.18 (t, J = 7.9 Hz, 
1H), 6.93 (dd, J = 12.9, 5.4 Hz, 2H), 6.78 (d, J = 8.7 Hz, 1H), 4.73 (s, 2H).
 13
C NMR (101 MHz, 
99 
 
CDCl3) δ 134.92, 130.85, 130.53, 128.60, 126.81, 126.47, 123.16, 121.87, 120.07.  HRMS (ESI): 
C13H11ClN2 Calcd. for ([M+H]
+
) 231.0686, found 231.0687. 
 
N’-m-bromophenyl benzamidine (m-BrPhB) (228):  Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc= 1:4, R f  = 0.81) to give 
N’-m-bromo-phenyl benzamidine as a white solid, 168.6 mg, 62 % yield. Mp: 126.9 - 127.9
 °
C. 
1
H 
NMR (400 MHz, CDCl3) δ 7.81 (s, 2H), 7.62 – 7.29 (m, 3H), 7.15 (d, J = 20.3 Hz, 3H), 6.88 (s, 
1H), 4.90 (s, 2H).
 13
C NMR (101 MHz, CDCl3) δ 155.04, 151.47, 135.35, 130.85, 130.77, 128.55, 
126.75, 125.90, 124.66, 123.06, 120.49. C13H11N2Br Calcd. for ([M+H]
+
) 276.0, found 276.0. 
 
N’-p-bromophenyl benzamidine (p-BrPhB) (229):  Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc= 1:4, R f  = 0.62) to give 
N’-p-bromo-phenyl benzamidine as a white solid, 138.5 mg, 50 % yield. Mp: 146.4 - 147.3
 °
C.
1
H 
NMR (400 MHz, CDCl3): δ 6.48 (s, 2H), 6.88 (d, 2H, J = 7.80 Hz), 7.32 (d, 2H, J = 8.09 Hz), 7.41-
7.54 (m, 3H), 7.97 (s, 2H). 
13
C NMR (100 MHz, CDCl3): δ 154.5, 154.4, 135.7, 128.9, 127.9, 
127.1, 125.5, 123.5. MS (ESI): C13H11N2Br Calcd. for ([M+H]
+
) 276.0, found 276.0. 
 
N’-p-cyano-phenyl benzamidine (p-CNPhB)(230):  Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes:EtOAc= 1:4, R f  = 0.70) to give 
N’-p-cyano-phenyl benzamidine as a yellow solid, 153.2 mg, 69 % yield  Mp: 146.4 - 147.3
 °
C. 
1
H 
NMR (400 MHz, CDCl3): δ 4.98 (s, 2H), 6.99 (d, 2H, J = 6.99 Hz), 7.38-7.48 (m, 3H), 7.55 (d, 2H, 
J = 7.86 Hz), 7.76 (s, 2H). 
13
C NMR (100 MHz, CDCl3): δ 155.5, 154.7, 135.1, 134.1, 133.9, 
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133.2, 131.3, 128.9, 127.1, 122.9, 119.7, 114.6, 105.9. HRMS (ESI): C14H11N3 Calcd. for ([M+H]
+
) 
222.1026, found 222.1017. 
 
N’-p-nitro-phenyl benzamidine  (p-NO2PhB) (231): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf  = 0.88), to give N’-
p-nitro-phenyl benzamidine as a white solid, 136.3 mg, 59 % yield. Mp: 150.0-151.9 
°
C.
 1
H NMR 
(400 MHz, CDCl3) δ 8.18 (d, J = 8.0 Hz, 2H), 8.02 (d, J = 9.1 Hz, 1H), 7.83 (s, 2H), 7.47 (dd, J = 
15.3, 7.0 Hz, 3H), 7.04 (d, J = 7.4 Hz, 2H), 6.58 (d, J = 9.0 Hz, 1H), 4.98 (s, 2H). 
13
C NMR (101 
MHz, CDCl3) δ 131.14, 128.71, 126.86, 126.30, 125.48, 122.12, 113.31. MS (ESI): C13H11N3O2 
Calcd. for ([M+H]
+
) 242.0, found 242.0. 
 
Nʹ-p-trifluoromethyl-phenyl benzamidine  (p-CF3PhB) (232): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f  = 
0.88) to give Nʹ-p-trifluoromethyl-phenyl benzamidine as a white solid, 136.3 mg, 59 % yield. Mp: 
150.0 - 151.9 
°
C. 
1
H NMR (250 MHz, DMSO-d6): δ 2.51 (br, s, 2H), 7.05 (d, 2H, J = 7.60 Hz), 7.48 
(t, 3H, J = 5.44 Hz), 7.63 (d, 2H, J = 8.00 Hz), 7.97 (s, 2H). 
13
C NMR (62.5 MHz, DMSO-d6): δ 
154.7, 135.4(q, J = 327.0 Hz) 130.2, 128.8, 128.0, 127.5, 126.2, 126.2, 126.1, 122.7, 122.3. 
HRMS (ESI): C14H11N2F3 Calcd. for ([M+H]
+
) 265.0947, found 265.0941. 
 
N’-(4-Trifluoromethoxy-phenyl)-benzamidine (p-OCF3PhB) (233): Following the 
general procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 
1:4, Rf = 0.85) to give N’-(4-Trifluoromethoxy-phenyl)-benzamidine as a cream color solid, 159.2 
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mg, 60 % yield. Mp: 134.3 - 135.5
 °
C. 
1
H NMR (100 MHz, CDCl3): δ 4.85 (br, s, 2H), 6.96 (d, 2H, J 
= 8.52 Hz), 7.17 (d, 2H, J = 7.95 Hz), 7.39-7.47 (m, 3H), 7.81 (s, 2H). 
13
C NMR (62.5 MHz, 
CDCl3): δ 155.4, 155.3, 148.6, 144.9, 135.6 (q, J = 327.0 Hz), 130.9, 128.8, 128.6, 126.9, 126.7, 
126.6, 122.9, 122.6, 122.1. MS (ESI): C14H11N2OF Calcd. for ([M+H]
+
) 281.0, found 281.0. 
 
N’-4-cyano-2-methyl-phenyl benzamidine (p-CNTB)(234): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 
0.85) to give N’-4-cyano-2-methyl-phenyl benzamidine as a light orange solid, 179.4 mg, 76 % 
yield. Mp: 138.5 - 139.7 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 2.22 (s, 2H), 4. 82(s, 2H), 7.11 (s, 1H), 
7.27 (t, 2H, J = 6.99 Hz), 7.431-7.49 (m, 4H), 7.85 (d, 2H, J = 6.54 Hz) 
13
C NMR (100 MHz, 
CDCl3): δ 154.8, 149.3, 136.3, 135.2, 131.8, 131.2, 129.2, 128.9, 127.3, 126.9, 126.7,  126.5, 
124.6, 119.4, 110.6, 18.3. HRMS (ESI) C15H13N3 Calcd. for ([M+H]
+
) 236.1182, found 236.1187. 
 
Nʹ-m-cyano-p-fluoro-phenyl benzamidine  (mCN-pFTB)(235): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.70) to give N’-m-cyano-p-fluorol-phenyl benzamidine as a light yellow solid, 63.8 mg, 23 % 
yield. Mp: 173.5-174.5 
°
C. 
1
H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 6.4 Hz, 2H), 7.53 – 7.38 (m, 
3H), 7.20 (s, 3H), 4.89 (s, 2H).
 13
C NMR (101 MHz, CDCl3) δ 155.93, 146.78, 135.10, 131.14, 
128.70, 126.67, 125.59, 120.42, 117.70, 114.05. MS (ESI): C13H11N2F1 Calcd. for ([M+H]
+
) 239.9, 
found 239.9. 
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N’-4-chloro-2-methyl-phenyl Benzamidine (p-Cl-o-CH3 B) (236):  Following the 
general procedure 1, the product was obtained by silica gel chromatography (hexanes: EtOAc = 
1:4, Rf  = 0.79), to give N’-4-chloro-2-mehtyl-phenyl Benzamidine as a white solid, 111.6 mg, 46 % 
yield. Mp: 110.5-111.5
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 2.331 (s, 3H), 4.84 (br, s, 2H), 6.79 (d, 
1H, J= 8.24Hz), 6.84 (s, 1H), 7.27 (d, 1H, J= 8.32 Hz), 7.834-7.39 (m, 3H), 7.79 (d, 2H, J= 7.05 
Hz) 
13
C NMR (100 MHz, CDCl3): δ 155.487, 148.254, 137.282, 135.675, 130.917, 130.121, 
128.779, 128.644, 126.994, 124.330, 120.625, 20.358, HRMS (ESI): C14H13N2Cl Calcd. for 
([M+H]
+
) 245.08400, found 245.08435. 
 
N’-3,5-di-chloro-phenyl benzamidine (3,5-Cl-PhB) (237): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f  = 
0.95) to give N’-3,5-di-chloro-phenyl benzamidine as a white solid, 209.5 mg, 79 % yield. Mp: 
112.9 - 113.5 °C. 
1
H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.4 Hz, 2H), 7.46 (dd, J = 14.2, 7.1 
Hz, 4H), 7.05 (s, 1H), 6.88 (s, 2H), 4.90 (s, 2H).
 13
C NMR (101 MHz, CDCl3) δ 155.41, 135.59, 
135.08, 131.04, 128.65, 126.71, 123.00, 120.34. MS (ESI): C14H10N2Cl2 Calcd. for ([M+H]
+
) 
352.4, found 352.4. 
 
3-Nitro-N’-o-tolyl-benzamidine (m-NO2TB) (238): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.80) to give 3-
Nitro-N’-o-tolyl-benzamidine as an orange solid, 178.4 mg, 68 % yield. Mp: 76.8 - 77.5 °C. 
1
H 
NMR (400 MHz, CDCl3): δ 2.31 (s, 3H), 5.04 (br, s, 1H), 6.72 (d, 2H, J= 12.83 Hz), 6.87 (d, 1H, J 
= 7.39 Hz), 7.21 (t, 2H, J = 7.54 Hz),  7.53 (t, 1H, J = 7.90 Hz), 8.14 (t, 1H, J = 7.35 Hz), 8.22 (t, 
1H, J = 7.97 Hz), 8.60 (s, 1H). 
13
C NMR (100 MHz, CDCl3): δ 153.2, 148.8, 148.3, 139.7, 137.7, 
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133.2, 129.7, 125.2, 124.6, 122.2, 122.1, 118.5, 21.6. MS (ESI): C14H13N3O Calcd. for ([M+H]
+
) 
256.0, found 256.0.  
 
4-Methoxy-N’-o-tolyl-benzamidine (o-T-(p-OCH3B))(239): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.92), to give 4-Methoxy-N’-o-tolyl-benzamidine as a yellow solid, 63.0 mg, 52 % yield with 
spectral properties reported in the literature.
88
 Mp: 124.9 - 125.8 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 
2.17 (s, 3H), 3,84 (s, 3H), 4.62 (br, s, 2H), 6.84 (d, 2H, J = 7.59 Hz), 6.92 (q, 3H, J = 7.33 Hz, J = 
14.68 Hz), 6.97-7.13 (m, 2H), 7.81(d, 2H, J = 7.69 Hz) 
13
C NMR (100 MHz, CDCl3): δ 161.7, 
153.7, 153.7, 153.6, 153.5, 148.3, 130.9, 128.486, 128.3, 127.0, 123.2, 121.5, 113.971, 55.6, 
17.9, HRMS (ESI): C15H16ON2 Calcd. for ([M+H]
+
) 241.1335, found 241.1378.  
 
 
N’-o tolyl-amidine (o-TA)(240):  Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf  = 0.93) to give N’-o tolyl amidine 
as a light yellow solid, 63.5 mg, 42 % yield with spectral properties reported in the literature.
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Mp: 68.9 -69.8 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.86 (s, 1H), 2.24 (s, 3H), 6.97 (s, 1H), 7.14 (t, 
3H, J = 7.94 Hz) 
13
C NMR (100 MHz, CDCl3): δ 130.5, 126.8, 123.3, 122.3, 18.2. HRMS (ESI): 
C9H12N2 Calcd. for ([M+Na]
+
) 171.0892, found 171.1027. 
 
N’-o-tolyl isonicotinamidine (241): Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 0.32) to give N’-o-tolyl-
isonicotinamidine as a bright yellow solid, 76.9 mg, 37 % yield with spectral properties reported in 
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the literature.
86
 Mp: 175.6 - 176.6 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 2.14 (s, 3H), 4.87 (s, 2H), 
6.82 (d, 1H, J = 7.56 Hz), 6.99 (d, 1H, J = 7.28 Hz), 7.19 (t, 2H, J = 7.33 Hz), 7.74 (s, 2H), 8.68 
(s, 2H) 
13
C NMR (100 MHz, CDCl3): δ 151.9, 150.5, 147.5, 143.2, 131.4, 131.1, 129.4, 127.4, 
127.2, 123.8, 121.2, 120.9, 120.6, 17.8. HRMS (ESI): C13H13N3 Calcd. for ([M+H]
+
) 212.1182, 
found 212.1181.  
 
2,2-Dimethyl-N-o-tolyl propionamidine(2,2-MePhPropioA) (242): Following the 
general procedure 1, the product was obtained by silica gel chromatography (hexanes: EtOAc = 
1:4, Rf = 0.34) to give 2,2-Dimethyl-N-o-tolyl-propionamidine as a yellow oil, 34.8 mg, 23 % yield. 
1
H NMR (400 MHz, CDCl3): δ 1.31 (s, 9H), 2.08 (s, 3H), 3.97 (br, s, 1H), 6.72 (d, 1H, J= 7.36 Hz), 
6.82 (d, 1H, J= 7.11 Hz), 6.93-7.15 (m, 2H). 
13
C NMR (100 MHz, CDCl3): δ 130.884, 127.104, 
123.105, 121.603, 37.095, 28.777, 17.566. MS (ESI): C12H18N2 Calcd. for ([M+H]
+
) 191.0, found 
191.0.  
 
3-Nitro-N’-m-tolyl benzamidine (m-NO2TB) (245): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.85) to give 3-
Nitro-N’-m-tolyl-benzamidine as an orange solid, 178.3 mg, 65 % yield. 
1
H NMR (400 MHz, 
CDCl3) δ 8.67 (s, 2H), 8.31 – 8.26 (m, 2H), 8.22 (d, J = 7.3 Hz, 2H), 7.59 (t, J = 8.0 Hz, 2H), 7.24 
(t, J = 7.6 Hz, 2H), 7.05 (t, J = 8.7 Hz, 1H), 6.90 (t, J = 8.8 Hz, 3H), 6.82 – 6.67 (m, 4H), 5.00 (s, 
4H), 2.33 (s, 6H).
 13
C NMR (101 MHz, CDCl3) δ 148.20, 139.54, 137.71, 132.91, 129.61, 129.55, 
129.48, 125.20, 125.08, 124.36, 121.90, 121.81, 118.15, 116.46, 116.24, 21.42.  MS (ESI): 
C14H13N3O Calcd. for ([M+H]
+
) 256.0, found 256.0.  
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3-Nitro-N’-p-tolyl benzamidine (p-NO2TB) (246): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.64) to give 3-
Nitro-N’-p-tolyl-benzamidine as an yellow oil, 159.1 mg, 85 % yield.
 1
H NMR (400 MHz, CDCl3) δ 
8.68 (s, 4H), 8.28 (ddd, J = 21.3, 11.3, 4.0 Hz, 8H), 7.60 (t, J = 8.0 Hz, 4H), 7.24 (d, J = 1.2 Hz, 
1H), 7.16 (d, J = 8.0 Hz, 8H), 6.86 (d, J = 8.2 Hz, 8H), 4.95 (s, 9H), 2.32 (s, 12H). 
13
C NMR (101 
MHz, CDCl3) δ 152.53, 148.04, 137.65, 132.92, 130.23, 129.55, 125.06, 121.77, 121.06, 20.83. 
MS (ESI): C14H13N3O Calcd. for ([M+H]
+
) 256.0, found 256.0.  
 
3-Nitro-N’-phenyl benzamidine (p-NO2PhB) (247): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.20) to give 3-
Nitro-N’-phenyl-benzamidine as an yellow oil, 208.6 mg, 98 % yield. Mp. 147.7 - 148.4 °C.
  1
H 
NMR (400 MHz, DMSO-d6) δ 12.15 (s, 1H), 10.19 (s, 1H), 9.20 (s, 1H), 8.79 (s, 1H), 8.55 (d, J = 
8.1 Hz, 1H), 8.37 (d, J = 7.7 Hz, 1H), 7.91 (t, J = 8.0 Hz, 1H), 7.61 – 7.38 (m, 5H). 
13
C NMR (101 
MHz, DMSO-d6) δ 161.71, 147.74, 136.03, 134.77, 130.88, 130.37, 128.83, 128.28, 125.85, 
124.81, 83.94. MS (ESI): C13H11N3O2 Calcd. for ([M+H]
+
) 242.0, found 242.0.  
 
3-Nitro-N’-o-fluorophenyl benzamidine (m-NO2-o-FPhB) (248): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.80) to give 3-Nitro-N’-o-fluorophenyl-benzamidine as yellow solid, 105.4 mg, 43 % yield. Mp: 
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92.5 - 93.5 °C. 
1
H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.29 (d, J = 8.1 Hz, 1H), 8.24 (d, J = 6.8 
Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.15 – 6.97 (m, 4H), 5.05 (s, 2H).
 13
C NMR (101 MHz, CDCl3) δ 
154.94, 152.50 , 148.17, 137.02 , 133.12 , 129.62, 125.32 , 124.93 (d, J = 3.6 Hz), 124.67 (d, J = 
7.2 Hz), 123.97 , 121.94, 116.44 (d, J = 19.9 Hz). MS (ESI): C13H10N3O2F Calcd. for ([M+H]
+
) 
260.0, found 260.0. 
 
3-Nitro-N’-m-fluorophenyl benzamidine (m-NO2-m-FPhB) (249): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.67) to give 3-Nitro-N’-m-fluorophenyl-benzamidine as yellow solid, 105.4 mg, 43 % yield. Mp: 
92.5 - 93.5 °C.  
1
H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 85.6 Hz, 1H), 8.28 (d, J = 7.5 Hz, 1H), 
8.20 (d, J = 5.2 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 12.6 Hz, 1H), 6.89 – 6.54 (m, 3H), 
5.07 (s, 2H).
 13
C NMR (101 MHz, CDCl3) δ 164.96, 162.50, 152.52, 148.19, 137.14, 132.87, 
130.92, 130.83, 129.64, 125.29, 121.84, 117.00, 110.39, 110.18, 108.70, 108.48. MS (ESI): 
C13H10N3O2F Calcd. for ([M+H]
+
) 260.0, found 260.0. 
 
3-Nitro-N’-naphth-2-yl-benzamidine (m-NO2-2-NaphB) (250): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.32) to give 3-Nitro-N’-naphth-2-yl--benzamidine as orange solid, 174.0 mg, 54 % yield. Mp: 157 
- 159 °C. NMR (400 MHz, CDCl3) δ 8.61 (s), 8.25 (d, J = 7.5 Hz), 8.15 (d, J = 6.6 Hz), 7.57 (t, J = 
8.0 Hz), 7.43 (d, J = 8.3 Hz), 6.81 (d, J = 8.3 Hz), 5.08 (s). MS (ESI): C13H10N3O2Br Calcd. for 
([M+H]
+
) 320.0, found 320.0. 
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3-Nitro-N’-p-bromophenyl benzamidine (m-NO2-p-BrPhB) (251): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.86) to give 3-Nitro-N’-naphth2-yl-benzamidine as orange solid, 51.1 mg, 18 % yield. Mp: 118.6 - 
119.6 °C.
 1
H NMR (250 MHz, CDCl3) δ 8.65 (s, 1H), 8.21 (s, 2H), 7.71 (dd, J = 15.1, 7.9 Hz, 3H), 
7.54 (s, 1H), 7.47 – 7.19 (m, 3H), 7.09 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H).
 13
C NMR (63 MHz, 
CDCl3) δ 148.25, 137.46, 134.50, 133.01, 130.57, 129.70, 127.79, 127.16, 126.39, 125.28, 
124.69, 122.23, 121.91, 117.40. MS (ESI): C17H13N3O2Br Calcd. for ([M+H]
+
) 292.1, found 292.1. 
 
 
N’-m-tolyl amidine (m-TA)(253):  Following the general procedure 1, the product was 
obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 0.93) to give N’-m tolyl 
amidine as a light yellow solid, 126.4 mg, 84 % yield with spectral properties reported in the 
literature.
168
 Mp: 68.9 - 69.8 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.97 (s, 1H), 2.32 (s, 3H), 6.83 (d, 
1H, J = 6.94 Hz), 6.97 (br, s, 2H), 7.15 (t, 1H, J = 7.51 Hz) 
13
C NMR (100 MHz, CDCl3): δ 138.9, 
128.9, 123.6, 121.8, 118.2, 21.7. MS (ESI): C9H12N2 Calcd. for ([M+H]
+
) 150.1, found 150.1. 
 
N’-2,4 dimethylphenyl amidine (2,4DCH3PhA)(254):  Following the general procedure 
1, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.83)  to 
give N’-2,4-dimethyl-phenyl amidine as a light yellow solid, 74.6 mg, 65 % yield with spectral 
properties reported in the literature.
168
 Mp: 134.9 - 135.5 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.89 
(br, s, 2H), 2.19 (s, 4H), 2.28 (s, 3H), 6.97 (t, 3H, J = 12.94 Hz). 
13
C NMR (100 MHz, CDCl3): δ 
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154.4, 131.4, 131.4, 127.4, 122.6, 122.4, 121.6, 21.0, 18.1, HRMS (ESI): C10H14N2 Calcd. for 
([M+Na]
+
) 185.114, found 185.1213.  
 
N’-phenyl amidine (PhA) (255):  Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes:EtOAc = 1:4, Rf = 0.90) to give N’-phenyl 
amidine as a light yellow solid, 92.3 mg, 84 % yield with spectral properties reported in the 
literature.
167, 168
 Mp: 124.8 - 126.2
 °
C. 
1
H NMR (400 MHz, CDCl3): δ 1.97 (s, 3H), 7.02 (t, 1H, J = 
7.15 Hz), 7.20 (s, 2H), 7.28 (t, 4H, J = 7.44 Hz), 
13
C NMR (100 MHz, CDCl3): δ 153.2, 129.2, 
122.9, 121.3, 18.9. MS (ESI): C8H10N2 Calcd. for ([M+H]
+
) 134.1, found 134.1.  
 
N’-p-tertbutyl phenyl amidine (t-BuPhA)(256):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.95) to give N’-
p-tertbutyl-phenyl amidine as a white solid, 101.0 mg, 52 % yield with spectral properties reported 
in the literature.
168
 Mp: 111.9 - 112.7 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.30 (s, 12H), 1.97 (br s, 
1H), 7.10 (s, 2H,), 7.28 (d, 3H, J = 8.01 Hz) 
13
C NMR (100 MHz, CDCl3): δ 125.9, 120.8, 77.6, 
77.2, 76.9, 34.4, 31.7. MS (ESI): C12H18N2 Calcd. for ([M+H]
+
) 190.1 found 190.1  
 
N’-o-fluorophenyl amidine  (o-FPhA)(257):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.95) to give N’-
o-fluoro-phenyl amidine as a yellow solid, 82.8 mg, 47 % yield with spectral properties reported in 
the literature.
168
 Mp: 99.8 - 100.7 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.99 (s, 3 H), 6.94-7.01 (d d, 
2H, J = 6.06 Hz, J= 7.90 Hz), 7.05-7.14 (m, 2H), 7.79 (br, s, 2H) 
13
C NMR (100 MHz, CDCl3): δ 
154.6 (d, J = 244.0 Hz), 152.1, 124.6 (d, J = 19.3 Hz), 123.2, 115.4 (d, J= 19 Hz), 115.2, 19.1. 
MS (ESI): C8H9N2F Calcd. for ([M+H]
+
) 153.0, found 153.0.  
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Nʹ-p-fluorophenyl amidine (p-FPhA)(258):  Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.92) to give Nʹ-
p-fluorophenyl amidine as a cream color solid, 109.7 mg, 69 % yield with spectral properties 
reported in the literature.
167
 Mp: 95.6 - 96.8 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.98 (s, 3H), 4.53 
(br, s, 2H), 6.70 (d, 2H, J = 6.91 Hz), 7.35 (d, 2H, J = 8.02 Hz), 
13
C NMR (100 MHz, CDCl3): δ 
155.826 (d, J = 242.2 Hz)  149.0, 132.5, 124.163 (d, J = 24.4 Hz), 123.9, 115.7, 109.9 (d= 19.2 
Hz), 22.7. MS (ESI): C8H9N2F Calcd. for ([M+H]
+
) 153.0, found 153.0.  
 
N’-p-fluoromethyl-phenyl amidine  (o-CF3PhA)(259):  Following the general procedure 
1, the product was obtained by silica gel chromatography (hexanes:EtOAc = 1:4, R f = 0.92) to 
give N’-p-fluoromethyl-phenyl amidine as a yellow solid, 127.9 mg, 62 % yield with spectral 
properties reported in the literature.
167
 Mp: 99.8 - 100.7 
°
C. 
1
H NMR (400 MHz, CDCl3): δ 1.97 (s, 
3 H), 6.41 (b, s, 1H), 7.30 (br, s, 1H), 7.54 (d, 2H, J = 8.28 Hz) 
13
C NMR (100 MHz, CDCl3): δ 
152.6, 126.4 124.7, 123.3, 120.7(q, J = 287 Hz), 120.4, 18.8 MS (ESI): C9H9N2F3 Calcd. for 
([M+H]
+
) 203.0, found 203.0.  
 
N’-phenyl-isonicotinamidine (262): Following the general procedure, the product was 
obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 0.20) to give N’-phenyl-
isonicotinamidine as a bright yellow solid, 88.1 mg, 50 % yield with spectral properties reported in 
the literature.
86 
Mp: 147.7 - 148.4 
°
C. 
1
H NMR (400 MHz, cdcl3) δ 8.62 (s, 2H), 7.68 (s, 2H), 7.32 
(t, J = 7.2 Hz, 2H), 7.05 (t, J = 7.1 Hz, 1H), 6.91 (d, J = 7.5 Hz, 2H), 5.07 (s, 2H).
 13
C NMR (101 
110 
 
MHz, CDCl3) δ 150.20, 149.09, 143.16, 129.63, 123.47, 121.18, 121.01. MS (ESI): C12H11N3 
Calcd. for ([M+H]
+
) 198.0, found 198.0.  
 
N’-p-bromophenyl isonicotinamidine (263): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 0.32) to give Nʹ-
p-bromo-phenyl-isonicotinamidine as a bright yellow solid,  164.8 mg, 60 % yield with spectral 
properties reported in the literature.
86 
M.p. 144.7 - 145.6 
°
C.
1
H NMR (400 MHz, CDCl3) δ 8.65 (s, 
1H), 7.68 (s, 1H), 7.43 (d, J = 7.4 Hz, 1H), 6.75 (dd, J = 45.3, 7.6 Hz, 1H), 5.06 (s, 1H).
 13
C NMR 
(101 MHz, CDCl3) δ 152.88, 150.29, 148.16, 142.72, 138.71, 132.64, 123.07, 120.91, 116.33, 
77.35, 77.03, 76.71. MS (ESI): C12H10BrN3 Calcd. for ([M+H]
+
) 277.9, found 277.9.  
 
N’-naphth-1-yl-isonicotinamidine (264): Following the general procedure, the product 
was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 0.20) to give N’-naphth-1-
yl-isonicotinamidine as a yellow solid, 88.1 mg, 20 % yield. 
 
M.p. 97.3 - 98.4 
°
C. 
1
H NMR (400 
MHz, CDCl3) δ 8.69 (s, 1H), 7.71 (s, 1H), 7.04 (s, 1H), 6.90 (s, 1H), 4.98 (s, 1H), 1.94 (s, 1H).  
13
C 
NMR (101 MHz, CDCl3) δ 160.85, 158.08, 153.07, 150.29, 144.77, 142.98, 122.39, 120.96, 
116.46, 116.23, 77.31, 76.99, 76.68. MS (ESI): C13H13N3 Calcd. for ([M+H]
+
) 248.0, found 248.0. 
 
6.4 Experimental Procedure for Chapter 4, Section 4.3 
To a screw-cap reaction tube was added guanidine nitrate (0.5 mmol, 0.0611 g), benzoic 
acid (1 mmol, 0.0611 g), HATU (1.1 eq., 0.2090 g), and DIPEA (0.61 g, 7 eq.). The reaction tube 
was placed under high vacuum and backfilled with Argon and repeated three times. Toluene (2 
mL) was added using a syringe. After the resulting solution was stirred for 24 hours, the product 
was extracted using ethyl acetate, washed with water 3 times, and the organic layer was dried 
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over anhydrous Na2SO4. Following concentration under reduced pressure, the residue was 
purified by silica gel chromatography (4:1:0.25 to 4:1:0.75 EtOAc: Hexanes: Et 3N) = to afford the 
desired product. 
 
N,N’-(iminomethylene)-di-(2-methylbenzamide) (269): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.77) to give N,N’-(iminomethylene)-di-(2-methylbenzamide) as a white solid, 64.2g, 87 % yield. 
Mp: 107.9 -109.2 
°
C. 
1
H NMR (400 MHz, DMSO-d6) δ 9.47 (s, 1H), 7.72 – 7.64 (m, 1H), 7.35 (td, 
J = 7.5, 1.3 Hz, 1H), 7.23 (dd, J = 10.1, 3.5 Hz, 2H), 2.43 (s, 3H). 
13
C NMR (101 MHz, DMSO-d6) 
δ 158.79, 137.19, 131.35, 130.93, 129.17, 125.87, 20.86. MS (ESI): C17H17N3O2 Calcd. for 
([M+H]
+
) 296.1, found 296.1. 
 
N,N’-(iminomethylene)-di-(3-methylbenzamide) (270): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 
0.75), to give N,N’-(iminomethylene)-di-(3-methylbenzamide) as a white solid, 58.9g, 76 % yield. 
Mp: 155.6 -156.5
°
C.
 1
H NMR (250 MHz, DMSO-d6) δ 9.39 (s, 1H), 7.89 (dd, J = 15.2, 11.1 Hz, 
4H), 7.43 (d, J = 5.7 Hz, 4H), 2.40 (s, 6H).
 13
C NMR (63 MHz, DMSO-d6) δ 158.77, 137.69, 
133.14, 129.00, 128.30, 125.64, 20.74. MS (ESI): C17H17N3O4 Calcd. for ([M+H]
+
) 296.1, found 
96.1. 
 
N,N’-(iminomethylene)-di-(4-methylbenzamide) (271): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
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0.81) to give N,N’-(iminomethylene)-di-(4-methylbenzamide) as a white solid, 68.6mg, 89 % yield. 
Mp: 178.6 -179.4 
°
C. 
1
HNMR (400 MHz, CDCl3) δ 7.98 (d, J = 7.7 Hz, 2H), 7.26 (d, J = 7.8 Hz, 
2H), 2.39 (d, J = 10.2 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 163.77, 134.21, 133.69, 45.33, 
45.13, 44.92, 44.71, 44.50, 44.29, 44.08, 26.30. MS (ESI): C17H17N3O2 Calcd. For ([M+H]
+
) 296.0, 
found 296.0  
 
N,N’-(iminomethylene)-di-(2,4-dimethylbenzamide) (272): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 
0.89) to give N,N’-(iminomethylene)-di-(2,4-dimethylbenzamide): as a white solid, 78.0 mg, 73 % 
yield. Mp: 188.6 - 189.2 
°
C. 
1
H NMR (400 MHz, DMSO-d6) δ 11.39 (s, 2H), 7.82 (d, J = 8.5 Hz, 
1H), 7.47 (d, J = 11.0 Hz, 2H), 7.07 (d, J = 27.2 Hz, 6H), 2.32 (d, J = 25.7 Hz, 12H). MS (ESI): 
C19H21N3O2 Calcd. For ([M+H]
+
) 324.0, found 324.0.  
 
N,N’-(iminomethylene)-di-(benzamide) (268): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 0.89) to give  as 
a white solid, 577 mg, 86 % yield . Mp: 153.2 - 154.4 
°
C.  
1
H NMR (400 MHz, CDCl3) δ 8.12 – 
8.03 (m, 2H), 7.56 (t, J = 7.3 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 
159.42, 132.71, 128.24. MS (ESI): C15H13N3O2  Calcd. for ([M+H]
+
) 268.0, found 268.0.  
 
N,N’-(iminomethylene)-di-(1-naphthamide) (273): Following the general procedure, the 
product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.89) to give 
N,N’-(iminomethylene)-di-(1-naphthamide) as a white solid, 78.0 mg, 85 % yield. Mp.188.6 - 
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189.6 
°
C. 
1
H NMR (400 MHz, CDCl3) δ 8.68 (s, 2H), 8.15 (d, J = 8.0 Hz, 2H), 8.00 (d, J = 7.5 Hz, 
3H), 7.91 (dd, J = 15.6, 8.3 Hz, 4H), 7.66 – 7.53 (m, 4H). 
13
C NMR (101 MHz, CDCl3) δ 159.04, 
135.48, 132.60, 129.94, 129.51, 129.32, 128.46, 128.28, 127.74, 126.72, 124.35. MS (ESI): 
C23H17N3O2 Calcd. for ([M+H]
+
) 368.0, found 368.0. 
 
N,N’-(iminomethylene)-di-(4-methoxybenzamide) (274): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.75) to give N,N’-(iminomethylene)-di-(4-methoxybenzamide) as a yellow solid, 60.1g, 73%. Mp: 
144.3 -145.9 
°
C.
 1
H NMR (250 MHz, DMSO-d6) δ 12.80 (s, 1H), 9.22 (s, 1H), 8.08 (d, J = 8.6 Hz, 
4H), 7.20 – 6.99 (m, 4H), 3.86 (s, 6H).
13
C NMR (101 MHz, CDCl3) δ 130.68, 113.82, 55.45.  MS 
(ESI): C17H17N3O4 Calcd. for ([M+H]
+
) 328.1, found 328.1. 
 
N,N’-(iminomethylene)-di-(4-iodobenzamide) (277): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 0.91) to give 
N,N’-(iminomethylene)-di-(4-iodobenzamide) as a yellow solid, 70.4 mg, 54%. Mp: 199.0 - 200.9 
°
C. 
1
H NMR (400 MHz, DMSO-d6) δ 12.32 (s, 1H), 9.40 (s, 2H), 7.85 (dd, J = 31.3, 6.7 Hz, 8H). 
13
C NMR (62.5 MHz, DMSO-d6) δ 158.81, 137.33, 130.35. MS (ESI) C15H11I2N3O2  Calcd. For 
([M+H]
+
) 519.6, found 519.6. 
 
N,N’-(iminomethylene)-di-(4-bromobenzamide) (276): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.95), to give N,N’-(iminomethylene)-di-(4-bromobenzamide) as a cream solid, 68.6 mg, 65%. 
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Mp: 205.4 - 206.9 
°
C. 
1
H NMR (400 MHz, DMSO-d6) δ 12.31 (s, 1H), 9.41 (s, 2H), 7.97 (d, J = 8.1 
Hz, 4H), 7.71 (d, J = 8.3 Hz, 4H). 
13
C NMR (101 MHz, DMSO-d6) δ 159.43, 131.90, 131.00. MS 
(ESI) C15H11Br2N3O2  Calcd. For ([M+H]
+
) 425.0, found 425.0. 
 
N,N’-(iminomethylene)-di-(4-fluorobenzamide) (277): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 0.97) to give 
N,N’-iminomethylene-di-(4-Fluorobenzamide) as a white solid, 54.4 mg, 72 % yield. M.p: 199.9-
201.0 
°
C. 
1
H NMR (250 MHz, DMSO-d6) δ 12.42 (s, 1H), 9.46 (s, 2H), 8.20 (s, 4H), 7.40 (s, 
4H).
13
C NMR (101 MHz, DMSO-d6) δ 166.44, 163.91, 159.11, 132.18, 115.94, 115.56, 39.95. MS 
(ESI): C15H11F2N3O2  Calcd. For ([M+H]
+
) 304.0, found 304.0 
  
N,N’-(iminomethylene)-di-(4-nitrobenzamide) (278): Following the general procedure, 
the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 0.89) to give 
N,N’-(iminomethylene)-di-(4-nitrobenzamide) as a yellow solid, 11.9g, 6 % yield. Mp: 241.0 - 
242.6 
°
C.
 1
H NMR (250 MHz, DMSO-d6) δ 12.38 (s, 1H), 9.74 (s, 2H), 8.40 (dd, J = 19.9, 8.0 Hz, 
8H).
 13
C NMR (63 MHz, DMSO-d6) δ 129.97, 123.47. MS (ESI): C15H11N5O6 Calcd. for ([M+H]
+
) 
358.1, found 358.1. 
 
N,N’-(iminomethylene)-di-(3-chlorobenzamide) (279): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 
0.98) to give N,N’-(iminomethylene)-di-(3-chlorobenzamide) as a white solid, 57.8g, 69 % yield. 
Mp: 135.4 -136.6 
°
C.
 1
H NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 7.95 (dd, J = 46.3, 9.2 Hz, 4H), 
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7.61 – 7.30 (m, 4H).
 13
C NMR (101 MHz, CDCl3) δ 158.96, 134.86, 132.83, 129.86, 128.84, 
126.34. MS (ESI): C15H11Cl2N3O2 Calcd. for ([M+H]
+
) 337.1, found 337.1. 
 
N,N’-(iminomethylene)-di-(4-bromo-2-methylbenzamide) (280): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.67) to give N,N’-(iminomethylene)-di-(4-bromo-2-methylbenzamide) as a white solid, 102.6g, 
97% yield. Mp: 143.9 - 144.9 
°
C.
 1
H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 3.8, 1.1 Hz, 1H), 7.60 
(d, J = 4.7 Hz, 1H), 7.13 (dd, J = 4.9, 3.8 Hz, 1H). MS (ESI): C17H15 Br2N5O6 Calcd. for ([M+H]
+
) 
454.1, found 454.1. 
 
N,N’-(iminomethylene)-di-(furan-3-carboxamide) (283): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f  = 
0.75) to give N,N’-(iminomethylene)-di-(furan-3-carboxamide) as a white solid, 117.7 mg, 95 % 
yield. M.p. 187.9 - 188.6 
°
C. 
1
H NMR (400 MHz,CDCl3) δ 9.45 (s, 3H), 7.57 (dd, J = 1.6, 0.7 Hz, 
2H), 7.27 (dd, J = 3.5, 0.6 Hz, 2H), 6.52 (dd, J = 3.5, 1.7 Hz, 2H).
 13
C NMR (101 MHz, CDCl3) δ 
158.74, 146.02, 117.52, 112.49. MS (ESI): C11H9N3O4 Calcd. for ([M+H]
+
) 248.1, found 248.1. 
 
N,N’-(iminomethylene)-di-(5-methylfuran-3-carboxamide) (284): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.89) to give N,N’-(iminomethylene)-di-(5-methylfuran-3-carboxamide) as a white solid, 46.2 mg, 
67% yield. M.p. 188.6 - 189.2 
°
C. 
1
H NMR (400 MHz,DMSO-d6) δ 12.38 (s, 1H), 9.00 (s, 2H), 7.25 
(s, 2H), 6.30 (s, 2H), 2.35 (d, J = 11.6 Hz, 6H). 
13
C NMR (101 MHz, DMSO-d6) δ 158.71, 119.17, 
109.51, 104.27, 14.07. MS (ESI): C13H13N3O4 Calcd. for ([M+H]
+
) 276.0, found 276.0.  
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N,N’-(iminomethylene)-di-(thiophen-3-carboxamide) (285): Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, R f = 
0.85) to give N,N’-(iminomethylene)-di-(thiophen-3-carboxamide)  as a white solid, 40.4 mg, 59 % 
yield. Mp: 172.2 - 173.8 °C. 
1
H NMR (250 MHz, DMSO-d6) δ 12.36 (s, 1H), 9.35 (s, 2H), 7.99 (s, 
4H), 7.29 (d, J = 3.7 Hz, 2H). 
13
C NMR (63 MHz, DMSO-d6) δ 158.37, 131.58, 128.36. MS (ESI): 
C11H9N3O2S2 Calcd. for ([M+H]
+
) 280.1, found 280.1. 
 
N,N’-(iminomethylene)-di-(4-bromo-2-methylbenzamide) (286);: Following the general 
procedure, the product was obtained by silica gel chromatography (hexanes: EtOAc = 1:4, Rf = 
0.67), to give N,N’-(iminomethylene)-di-(4-bromo-2-methylbenzamide) as a white solid, 102.6 mg, 
97 % yield. Mp: 143.9 - 144.9
°
C . 
1
H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.58 (s, 1H), 7.39 (s, 
1H), 6.97 (s, 1H), 2.26 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 159.44, 136.91, 136.28, 133.81, 
133.06, 131.55, 118.86, 20.11. C17H15Br2N3O2 Calcd. For ([M+H]
+
) 454.0, found 454.0 
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CHAPTER 7 
 
SPECTRA 
 
7.1 
1
H NMR and 
13
C NMR for Chapter 4, Section 4.1 
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Spectra 2 Compound 1a 
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Spectra 3 Compound 172 
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Spectra 4 Compound 173  
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Spectra.5 Compound 174 
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Spectra 6 Compound 175 
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Spectra 7 Compound 176  
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Spectra 8 Compound 177 
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Spectra 9 Compound 178 
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Spectra 10 Compound 179  
 
 p p m (t1 )
5 .01 0 .0
6
.9
3
8
6
.9
0
6
6
.8
9
6
2
.2
0
8
2
.1
5
3
3
.0
0
2
.8
3
3
.5
9
1
.8
8
127 
 
Spectra 11 Compound 180 
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Spectra 12 Compound 182 
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Spectra 13 Compound 183 
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Spectra 14 Compound 184 
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Spectra 15 Compound 185 
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Spectra 16 Compound 186 
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